

Draft for consultation

Type 2 diabetes in adults: management (medicines update)

[E2.3] Evidence reviews for initial pharmacological management of type 2 diabetes: appendix L

NICE guideline GID-NG10336

Evidence reviews underpinning recommendations 1.8.6-1.8.32, 1.8.34, 1.8.38-1.8.60 and recommendations for research in the NICE guideline

August 2025

Draft for Consultation

This evidence review was developed by NICE

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2025. All rights reserved. Subject to [Notice of Rights](#).

ISBN:

Contents

Appendices..... 5
 Appendix L Baseline HbA1c, weight and BMI values..... 5

Appendices

Appendix L Baseline HbA1c, weight and BMI values

Table 1: Baseline characteristic HbA1c, weight and BMI values for studies included in the review

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Aggarwal 2018	Metformin slow release; 500-2000 mg daily; Oral	BMI change	kg/m2	32.9	5.5	Not applicable	Not applicable	Not applicable	268
Aggarwal 2018	Metformin standard release; 500-2000 mg daily; Oral	BMI change	kg/m2	32.8	5.4	Not applicable	Not applicable	Not applicable	271
Arjona Ferreira 2013A	Glipizide; 2.5-20 mg daily; Oral	BMI change	kg/m2	27.3	5.7	Not applicable	Not applicable	Not applicable	64
Arjona Ferreira 2013A	Glipizide; 2.5-20 mg daily; Oral	HbA1c change	%	7.9	0.7	Not applicable	Not applicable	Not applicable	64
Arjona Ferreira 2013A	Sitagliptin; 25 mg daily; Oral	BMI change	kg/m2	26.3	4.3	Not applicable	Not applicable	Not applicable	65
Arjona Ferreira 2013A	Sitagliptin; 25 mg daily; Oral	HbA1c change	%	7.8	0.7	Not applicable	Not applicable	Not applicable	65

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Arjona Ferreira 2013B	Glipizide; 2.5-20 mg daily; Oral	BMI change	kg/m2	26.5	4.8	Not applicable	Not applicable	Not applicable	211
Arjona Ferreira 2013B	Glipizide; 2.5-20 mg daily; Oral	HbA1c change	%	7.8	0.7	Not applicable	Not applicable	Not applicable	211
Arjona Ferreira 2013B	Glipizide; 2.5-20 mg daily; Oral	Weight change	kg	68	14.8	Not applicable	Not applicable	Not applicable	211
Arjona Ferreira 2013B	Sitagliptin; 25-50 mg daily; Oral	BMI change	kg/m2	27	4.8	Not applicable	Not applicable	Not applicable	212
Arjona Ferreira 2013B	Sitagliptin; 25-50 mg daily; Oral	HbA1c change	%	7.8	0.7	Not applicable	Not applicable	Not applicable	212
Arjona Ferreira 2013B	Sitagliptin; 25-50 mg daily; Oral	Weight change	kg	70.2	15.9	Not applicable	Not applicable	Not applicable	212
Aroda 2019B	Placebo; None; Oral	BMI change	kg/m2	32.2	6.9	Not applicable	Not applicable	Not applicable	178
Aroda 2019B	Semaglutide; 14 mg daily; Oral	BMI change	kg/m2	31.7	6.6	Not applicable	Not applicable	Not applicable	175
Aroda 2019B	Semaglutide; 3 mg daily; Oral	BMI change	kg/m2	31.8	6.3	Not applicable	Not applicable	Not applicable	175
Aroda 2019B	Semaglutide; 3-14 mg daily	BMI change	kg/m2	31.7	6.44	Not applicable	Not applicable	Not applicable	525

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	combined; Oral								
Aroda 2019B	Semaglutide; 7 mg daily; Oral	BMI change	kg/m2	31.6	6.4	Not applicable	Not applicable	Not applicable	175
Aschner 2006	Placebo; None; Oral	BMI change	kg/m2	30.3	5.3	Not applicable	Not applicable	Not applicable	488
Aschner 2006	Placebo; None; Oral	HbA1c change	%	8.1	0.9	Not applicable	Not applicable	Not applicable	488
Aschner 2006	Placebo; None; Oral	Weight change	kg	84.3	18.8	Not applicable	Not applicable	Not applicable	488
Aschner 2006	Sitagliptin; 200 mg daily; Oral	BMI change	kg/m2	30.8	5.5	Not applicable	Not applicable	Not applicable	253
Aschner 2006	Sitagliptin; 200 mg daily; Oral	HbA1c change	%	8	0.8	Not applicable	Not applicable	Not applicable	253
Aschner 2006	Sitagliptin; 200 mg daily; Oral	Weight change	kg	85	18.1	Not applicable	Not applicable	Not applicable	253
Aschner 2010	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	30.9	4.9	Not applicable	Not applicable	Not applicable	522
Aschner 2010	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	30.7	4.7	Not applicable	Not applicable	Not applicable	528

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Bailey 2012	Dapagliflozin; 1 mg daily; Oral	BMI change	kg/m2	32.53	5.68	Not applicable	Not applicable	Not applicable	72
Bailey 2012	Dapagliflozin; 1 mg daily; Oral	HbA1c change	%	7.8	0.98	Not applicable	Not applicable	Not applicable	72
Bailey 2012	Dapagliflozin; 1-5 mg daily combined; Oral	BMI change	kg/m2	31.55	5.65	Not applicable	Not applicable	Not applicable	214
Bailey 2012	Dapagliflozin; 1-5 mg daily combined; Oral	HbA1c change	%	7.93	1.02	Not applicable	Not applicable	Not applicable	214
Bailey 2012	Dapagliflozin; 2.5 mg daily; Oral	BMI change	kg/m2	31.13	5.47	Not applicable	Not applicable	Not applicable	74
Bailey 2012	Dapagliflozin; 2.5 mg daily; Oral	HbA1c change	%	8.07	1.03	Not applicable	Not applicable	Not applicable	74
Bailey 2012	Dapagliflozin; 5 mg daily; Oral	BMI change	kg/m2	30.97	5.68	Not applicable	Not applicable	Not applicable	68
Bailey 2012	Dapagliflozin; 5 mg daily; Oral	HbA1c change	%	7.92	1.04	Not applicable	Not applicable	Not applicable	68
Bailey 2012	Placebo; None; Oral	BMI change	kg/m2	32.47	4.91	Not applicable	Not applicable	Not applicable	68

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Bailey 2012	Placebo; None; Oral	HbA1c change	%	7.8	1.12	Not applicable	Not applicable	Not applicable	68
Banerji 1995	Glipizide; 2.5 mg daily; Oral	BMI change	kg/m2	26.7	2.53	0.8	Not applicable	Not applicable	10
Banerji 1995	Glipizide; 2.5 mg daily; Oral	HbA1c change	%	4.6	0.57	0.18	Not applicable	Not applicable	10
Banerji 1995	Placebo; None; Oral	BMI change	kg/m2	27.5	3.16	1	Not applicable	Not applicable	10
Banerji 1995	Placebo; None; Oral	HbA1c change	%	4.7	0.54	0.17	Not applicable	Not applicable	10
Barzilai 2011	Placebo; None; Oral	BMI change	kg/m2	30.8	5.9	Not applicable	Not applicable	Not applicable	102
Barzilai 2011	Placebo; None; Oral	HbA1c change	%	7.8	0.8	Not applicable	Not applicable	Not applicable	102
Barzilai 2011	Placebo; None; Oral	Weight change	kg	85.6	16.6	Not applicable	Not applicable	Not applicable	102
Barzilai 2011	Sitagliptin; 50-100 mg daily; Oral	BMI change	kg/m2	31.1	7.2	Not applicable	Not applicable	Not applicable	104
Barzilai 2011	Sitagliptin; 50-100 mg daily; Oral	HbA1c change	%	7.8	0.7	Not applicable	Not applicable	Not applicable	104
Barzilai 2011	Sitagliptin; 50-100 mg daily; Oral	Weight change	kg	85.8	16.5	Not applicable	Not applicable	Not applicable	104

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Bi 2013	Glipizide; 15 mg daily; Oral	BMI change	kg/m2	24.6	2.68	0.3	Not applicable	Not applicable	80
Bi 2013	Glipizide; 15 mg daily; Oral	HbA1c change	%	8.1	1.79	0.2	Not applicable	Not applicable	80
Bi 2013	Metformin type unspecified; 1500 mg daily; Oral	BMI change	kg/m2	25.2	2.68	0.3	Not applicable	Not applicable	80
Bi 2013	Metformin type unspecified; 1500 mg daily; Oral	HbA1c change	%	8	1.79	0.2	Not applicable	Not applicable	80
Bosi 2009	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	31.31	4.58	Not applicable	Not applicable	Not applicable	294
Bosi 2009	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	8.62	0.93	Not applicable	Not applicable	Not applicable	294
Bosi 2009	Vildagliptin + high dose metformin;	BMI change	kg/m2	31.37	4.75	Not applicable	Not applicable	Not applicable	295

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	100 mg + 2000 mg daily; Oral								
Bosi 2009	Vildagliptin + high dose metformin; 100 mg + 2000 mg daily; Oral	HbA1c change	%	8.7	1.03	Not applicable	Not applicable	Not applicable	295
Bosi 2009	Vildagliptin + low dose metformin; 100 mg + 1000 mg daily; Oral	BMI change	kg/m2	31.06	4.9	Not applicable	Not applicable	Not applicable	290
Bosi 2009	Vildagliptin + low dose metformin; 100 mg + 1000 mg daily; Oral	HbA1c change	%	8.58	1.01	Not applicable	Not applicable	Not applicable	290
Bosi 2009	Vildagliptin + Metformin; 100 mg + 1000-2000 mg daily; Oral	BMI change	kg/m2	31.22	4.83	Not applicable	Not applicable	Not applicable	585
Bosi 2009	Vildagliptin + Metformin; 100 mg +	HbA1c change	%	8.64	1.02	Not applicable	Not applicable	Not applicable	585

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	1000-2000 mg daily; Oral								
Bosi 2009	Vildagliptin; 100 mg daily; Oral	BMI change	kg/m2	31.26	4.82	Not applicable	Not applicable	Not applicable	300
Bosi 2009	Vildagliptin; 100 mg daily; Oral	HbA1c change	%	8.68	1.02	Not applicable	Not applicable	Not applicable	300
Campbell 1994	Glipizide; 30 mg daily; Oral	BMI change	kg/m2	31.2	6.6	Not applicable	Not applicable	Not applicable	24
Campbell 1994	Glipizide; 30 mg daily; Oral	HbA1c change	%	11.8	2.11	Not applicable	Not applicable	Not applicable	24
Campbell 1994	Metformin type unspecified; 3000 mg daily; Oral	BMI change	kg/m2	29.6	5.6	Not applicable	Not applicable	Not applicable	24
Campbell 1994	Metformin type unspecified; 3000 mg daily; Oral	HbA1c change	%	11.5	1.9	Not applicable	Not applicable	Not applicable	24
Chakraborty 2011	Metformin type unspecified;	BMI change	kg/m2	27	2.4	Not applicable	Not applicable	Not applicable	110

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	850-2000 mg daily; Oral								
Chakraborty 2011	Metformin type unspecified; 850-2000 mg daily; Oral	HbA1c change	%	8.7	1.4	Not applicable	Not applicable	Not applicable	110
Chakraborty 2011	Placebo; None; Oral	BMI change	kg/m2	27	1.3	Not applicable	Not applicable	Not applicable	98
Chakraborty 2011	Placebo; None; Oral	HbA1c change	%	8.7	1.5	Not applicable	Not applicable	Not applicable	98
Charbonnel 2005	Gliclazide; 320 mg daily; Oral	HbA1c change	%	8.7	Not applicable	Not applicable	Not applicable	Not applicable	635
Charbonnel 2005	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	8.7	Not applicable	Not applicable	Not applicable	Not applicable	635
Chen 2015	Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	25.5	3.3	Not applicable	Not applicable	Not applicable	200
Chen 2015	Linagliptin; 5 mg daily; Oral	HbA1c change	%	7.95	0.89	Not applicable	Not applicable	Not applicable	200
Chen 2015	Linagliptin; 5 mg daily; Oral	Weight change	kg	69	11.6	Not applicable	Not applicable	Not applicable	200
Chen 2015	Placebo; None; Oral	BMI change	kg/m2	25.1	3.4	Not applicable	Not applicable	Not applicable	99

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Chen 2015	Placebo; None; Oral	HbA1c change	%	8.09	0.91	Not applicable	Not applicable	Not applicable	99
Chen 2015	Placebo; None; Oral	Weight change	kg	68.2	10.4	Not applicable	Not applicable	Not applicable	99
Chen 2018B	Dulaglutide; 0.75 mg weekly; Subcutaneous	BMI change	kg/m2	26.2	3.49	Not applicable	Not applicable	Not applicable	248
Chen 2018B	Dulaglutide; 0.75 mg weekly; Subcutaneous	HbA1c change	%	8	1.03	Not applicable	Not applicable	Not applicable	248
Chen 2018B	Dulaglutide; 0.75-1.5 mg weekly combined; Subcutaneous	BMI change	kg/m2	26	3.46	Not applicable	Not applicable	Not applicable	492
Chen 2018B	Dulaglutide; 0.75-1.5 mg weekly combined; Subcutaneous	HbA1c change	%	8	0.99	Not applicable	Not applicable	Not applicable	492
Chen 2018B	Dulaglutide; 1.5 mg weekly;	BMI change	kg/m2	25.8	3.43	Not applicable	Not applicable	Not applicable	244

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	Subcutaneous								
Chen 2018B	Dulaglutide; 1.5 mg weekly; Subcutaneous	HbA1c change	%	8	0.95	Not applicable	Not applicable	Not applicable	244
Chen 2018B	Glimepiride; 1-3 mg daily; Oral	BMI change	kg/m2	25.7	3.14	Not applicable	Not applicable	Not applicable	245
Chen 2018B	Glimepiride; 1-3 mg daily; Oral	HbA1c change	%	7.9	1.01	Not applicable	Not applicable	Not applicable	245
Chen 2022	Gliclazide + Saxagliptin; 120 mg + 5 mg daily; Oral	BMI change	kg/m2	25.9	3.1	Not applicable	Not applicable	Not applicable	216
Chen 2022	Gliclazide + Saxagliptin; 120 mg + 5 mg daily; Oral	HbA1c change	%	9.2	0.7	Not applicable	Not applicable	Not applicable	216
Chen 2022	Saxagliptin + Metformin; 5 mg + 2000 mg daily; Oral	BMI change	kg/m2	26	3.2	Not applicable	Not applicable	Not applicable	216

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Chen 2022	Saxagliptin + Metformin; 5 mg + 2000 mg daily; Oral	HbA1c change	%	9.2	0.8	Not applicable	Not applicable	Not applicable	216
Chiasson 2001	Metformin type unspecified; 1500 mg daily; Oral	BMI change	kg/m2	30.7	5.1	Not applicable	Not applicable	Not applicable	83
Chiasson 2001	Metformin type unspecified; 1500 mg daily; Oral	HbA1c change	%	8.2	0.9	Not applicable	Not applicable	Not applicable	83
Chiasson 2001	Placebo; None; Oral	BMI change	kg/m2	31.1	4.4	Not applicable	Not applicable	Not applicable	83
Chiasson 2001	Placebo; None; Oral	HbA1c change	%	8.1	0.7	Not applicable	Not applicable	Not applicable	83
Chou 2012	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	30	5.8	Not applicable	Not applicable	Not applicable	751
Chou 2012	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	7.7	0.58	Not applicable	Not applicable	Not applicable	751
Chou 2012	Placebo; None; Oral	BMI change	kg/m2	30.1	5.43	Not applicable	Not applicable	Not applicable	137

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Chou 2012	Placebo; None; Oral	HbA1c change	%	7.7	0.54	Not applicable	Not applicable	Not applicable	137
Chou 2012	Rivoglitazone ; 1 mg daily; Oral	BMI change	kg/m2	29.7	5.63	Not applicable	Not applicable	Not applicable	274
Chou 2012	Rivoglitazone ; 1 mg daily; Oral	HbA1c change	%	7.7	0.53	Not applicable	Not applicable	Not applicable	274
Chou 2012	Rivoglitazone ; 1.5 mg daily; Oral	BMI change	kg/m2	29.6	5.27	Not applicable	Not applicable	Not applicable	750
Chou 2012	Rivoglitazone ; 1.5 mg daily; Oral	HbA1c change	%	7.7	0.57	Not applicable	Not applicable	Not applicable	750
Chou 2012	Rivoglitazone ; 1-1.5 mg daily combined; Oral	BMI change	kg/m2	29.63	5.37	Not applicable	Not applicable	Not applicable	1024
Chou 2012	Rivoglitazone ; 1-1.5 mg daily combined; Oral	HbA1c change	%	7.7	0.56	Not applicable	Not applicable	Not applicable	1024
DeFronzo 1995	Metformin type unspecified; 500-2500 mg daily; Oral	BMI change	kg/m2	29.9	3.59	0.3	Not applicable	Not applicable	143

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
DeFronzo 1995	Metformin type unspecified; 500-2500 mg daily; Oral	HbA1c change	%	8.4	1.2	0.1	Not applicable	Not applicable	143
DeFronzo 1995	Metformin type unspecified; 500-2500 mg daily; Oral	Weight change	kg	94.4	13.15	1.1	Not applicable	Not applicable	143
DeFronzo 1995	Placebo; None; Oral	BMI change	kg/m2	29.2	3.62	0.3	Not applicable	Not applicable	146
DeFronzo 1995	Placebo; None; Oral	HbA1c change	%	8.2	2.42	0.2	Not applicable	Not applicable	146
DeFronzo 1995	Placebo; None; Oral	Weight change	kg	92.2	14.5	1.2	Not applicable	Not applicable	146
del Prato 2003	Metformin type unspecified; 2550 mg daily; Oral	BMI change	kg/m2	29.8	4.2	Not applicable	Not applicable	Not applicable	284
del Prato 2003	Metformin type unspecified; 2550 mg daily; Oral	HbA1c change	%	7.79	1.61	Not applicable	Not applicable	Not applicable	284
del Prato 2003	Metformin type unspecified;	Weight change	kg	82.6	14.6	Not applicable	Not applicable	Not applicable	284

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	2550 mg daily; Oral								
del Prato 2003	Placebo; None; Oral	BMI change	kg/m2	29.9	3.9	Not applicable	Not applicable	Not applicable	144
del Prato 2003	Placebo; None; Oral	HbA1c change	%	7.43	1.48	Not applicable	Not applicable	Not applicable	144
del Prato 2003	Placebo; None; Oral	Weight change	kg	84.5	14.8	Not applicable	Not applicable	Not applicable	144
Derosa 2004	Glimepiride; 4 mg daily; Oral	BMI change	kg/m2	27.6	1.2	Not applicable	Not applicable	Not applicable	81
Derosa 2004	Glimepiride; 4 mg daily; Oral	HbA1c change	%	8.5	1.2	Not applicable	Not applicable	Not applicable	81
Derosa 2004	Metformin type unspecified; 3000 mg daily; Oral	BMI change	kg/m2	28.1	1.5	Not applicable	Not applicable	Not applicable	83
Derosa 2004	Metformin type unspecified; 3000 mg daily; Oral	HbA1c change	%	8.4	1	Not applicable	Not applicable	Not applicable	83
Derosa 2009	Glimepiride + Metformin; 6 mg + 850 mg daily; Oral	BMI change	kg/m2	27.1	1.4	Not applicable	Not applicable	Not applicable	66

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Derosa 2009	Glimepiride + Metformin; 6 mg + 850 mg daily; Oral	HbA1c change	%	9	1.1	Not applicable	Not applicable	Not applicable	66
Derosa 2009	Glimepiride + Metformin; 6 mg + 850 mg daily; Oral	Weight change	kg	77.4	5.8	Not applicable	Not applicable	Not applicable	66
Derosa 2009	Metformin type unspecified; 3000 mg daily; Oral	BMI change	kg/m2	27.2	1.5	Not applicable	Not applicable	Not applicable	67
Derosa 2009	Metformin type unspecified; 3000 mg daily; Oral	HbA1c change	%	9.1	1.2	Not applicable	Not applicable	Not applicable	67
Derosa 2009	Metformin type unspecified; 3000 mg daily; Oral	Weight change	kg	77.7	5.9	Not applicable	Not applicable	Not applicable	67
Derosa 2009	Pioglitazone + Metformin; 45 mg + 2550 mg daily; Oral	BMI change	kg/m2	27.4	1.6	Not applicable	Not applicable	Not applicable	69

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Derosa 2009	Pioglitazone + Metformin; 45 mg + 2550 mg daily; Oral	HbA1c change	%	9.3	1.4	Not applicable	Not applicable	Not applicable	69
Derosa 2009	Pioglitazone + Metformin; 45 mg + 2550 mg daily; Oral	Weight change	kg	76.4	5.1	Not applicable	Not applicable	Not applicable	69
Derosa 2009	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	27.5	1.7	Not applicable	Not applicable	Not applicable	69
Derosa 2009	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	9.2	1.2	Not applicable	Not applicable	Not applicable	69
Derosa 2009	Pioglitazone; 45 mg daily; Oral	Weight change	kg	75.7	5.3	Not applicable	Not applicable	Not applicable	69
Dou 2018	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	26.5	3.6	Not applicable	Not applicable	Not applicable	210
Dou 2018	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	9.5	1	Not applicable	Not applicable	Not applicable	210

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Dou 2018	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	73.5	13.8	Not applicable	Not applicable	Not applicable	210
Dou 2018	Saxagliptin + Metformin; 5 mg + 2000 mg daily; Oral	BMI change	kg/m2	26.7	3.7	Not applicable	Not applicable	Not applicable	216
Dou 2018	Saxagliptin + Metformin; 5 mg + 2000 mg daily; Oral	HbA1c change	%	9.4	1.1	Not applicable	Not applicable	Not applicable	216
Dou 2018	Saxagliptin + Metformin; 5 mg + 2000 mg daily; Oral	Weight change	kg	73.7	13.1	Not applicable	Not applicable	Not applicable	216
Dou 2018	Saxagliptin; 5 mg daily; Oral	BMI change	kg/m2	26.5	3.2	Not applicable	Not applicable	Not applicable	214
Dou 2018	Saxagliptin; 5 mg daily; Oral	HbA1c change	%	9.4	1	Not applicable	Not applicable	Not applicable	214
Dou 2018	Saxagliptin; 5 mg daily; Oral	Weight change	kg	74.2	13.1	Not applicable	Not applicable	Not applicable	214

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Erem 2014	Gliclazide; 60 mg daily; Oral	BMI change	kg/m2	32.72	3.86	Not applicable	Not applicable	Not applicable	20
Erem 2014	Gliclazide; 60 mg daily; Oral	HbA1c change	%	8.26	1.65	Not applicable	Not applicable	Not applicable	20
Erem 2014	Gliclazide; 60 mg daily; Oral	Weight change	kg	90.06	18.13	Not applicable	Not applicable	Not applicable	20
Erem 2014	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	33.56	4.56	Not applicable	Not applicable	Not applicable	20
Erem 2014	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	7.62	1.06	Not applicable	Not applicable	Not applicable	20
Erem 2014	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	87.47	12.93	Not applicable	Not applicable	Not applicable	20
Erem 2014	Pioglitazone; 30 mg daily; Oral	BMI change	kg/m2	31.31	4.69	Not applicable	Not applicable	Not applicable	20

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Erem 2014	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	8.03	1.7	Not applicable	Not applicable	Not applicable	20
Erem 2014	Pioglitazone; 30 mg daily; Oral	Weight change	kg	81.93	13.43	Not applicable	Not applicable	Not applicable	20
Esposito 2011	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	29.1	3.3	Not applicable	Not applicable	Not applicable	55
Esposito 2011	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	8.1	1	Not applicable	Not applicable	Not applicable	55
Esposito 2011	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	83.5	8.5	Not applicable	Not applicable	Not applicable	55
Esposito 2011	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	28.9	3.5	Not applicable	Not applicable	Not applicable	55
Esposito 2011	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	8	1	Not applicable	Not applicable	Not applicable	55

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Esposito 2011	Pioglitazone; 45 mg daily; Oral	Weight change	kg	84.5	8.6	Not applicable	Not applicable	Not applicable	55
Feng 2017	Gliclazide; 120 mg daily B; Oral	HbA1c change	%	9.07	1.3	0.23	Not applicable	Not applicable	32
Feng 2017	Gliclazide; 120 mg daily; Oral	BMI change	kg/m2	27.5	2.83	0.5	Not applicable	Not applicable	32
Feng 2017	Gliclazide; 120 mg daily; Oral	HbA1c change	%	9.03	1.3	0.23	Not applicable	Not applicable	32
Feng 2017	Gliclazide; 120 mg daily; Oral	Weight change	kg	78.13	13.75	2.43	Not applicable	Not applicable	32
Feng 2017	Liraglutide; 1.8 mg daily B; Subcutaneous	HbA1c change	%	8.91	1.75	0.32	Not applicable	Not applicable	30
Feng 2017	Liraglutide; 1.8 mg daily; Subcutaneous	BMI change	kg/m2	28.1	3.29	0.6	Not applicable	Not applicable	30
Feng 2017	Liraglutide; 1.8 mg daily; Subcutaneous	HbA1c change	%	8.91	1.75	0.32	Not applicable	Not applicable	30

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Feng 2017	Liraglutide; 1.8 mg daily; Subcutaneous	Weight change	kg	81.1	12.6	2.3	Not applicable	Not applicable	30
Feng 2017	Metformin type unspecified; 2000 mg daily B; Oral	HbA1c change	%	9.36	1.84	0.33	Not applicable	Not applicable	31
Feng 2017	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	26.8	3.9	0.7	Not applicable	Not applicable	31
Feng 2017	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	9.36	1.84	0.33	Not applicable	Not applicable	31
Feng 2017	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	74.8	13.92	2.5	Not applicable	Not applicable	31
Ferrannini 2010	Dapagliflozin; 10 mg daily; Oral	BMI change	kg/m2	32.95	5.67	Not applicable	Not applicable	Not applicable	185

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Ferrannini 2010	Dapagliflozin; 10 mg daily; Oral	HbA1c change	%	8.54	1.46	Not applicable	Not applicable	Not applicable	185
Ferrannini 2010	Dapagliflozin; 10 mg daily; Oral	Weight change	kg	91.92	21.12	Not applicable	Not applicable	Not applicable	185
Ferrannini 2010	Dapagliflozin; 2.5 mg daily; Oral	BMI change	kg/m2	32.4	5.4	Not applicable	Not applicable	Not applicable	132
Ferrannini 2010	Dapagliflozin; 2.5 mg daily; Oral	HbA1c change	%	7.96	0.94	Not applicable	Not applicable	Not applicable	132
Ferrannini 2010	Dapagliflozin; 2.5 mg daily; Oral	Weight change	kg	89.53	21.62	Not applicable	Not applicable	Not applicable	132
Ferrannini 2010	Dapagliflozin; 2.5-10 mg daily combined; Oral	BMI change	kg/m2	32.66	5.36	Not applicable	Not applicable	Not applicable	483
Ferrannini 2010	Dapagliflozin; 2.5-10 mg daily combined; Oral	HbA1c change	%	8.35	1.38	Not applicable	Not applicable	Not applicable	484
Ferrannini 2010	Dapagliflozin; 2.5-10 mg daily	Weight change	kg	90.08	20.61	Not applicable	Not applicable	Not applicable	484

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	combined; Oral								
Ferrannini 2010	Dapagliflozin; 5 mg daily; Oral	BMI change	kg/m2	32.54	4.95	Not applicable	Not applicable	Not applicable	166
Ferrannini 2010	Dapagliflozin; 5 mg daily; Oral	HbA1c change	%	8.45	1.52	Not applicable	Not applicable	Not applicable	167
Ferrannini 2010	Dapagliflozin; 5 mg daily; Oral	Weight change	kg	88.48	19	Not applicable	Not applicable	Not applicable	167
Ferrannini 2010	Placebo; None; Oral	BMI change	kg/m2	32.3	5.5	Not applicable	Not applicable	Not applicable	75
Ferrannini 2010	Placebo; None; Oral	HbA1c change	%	7.84	0.87	Not applicable	Not applicable	Not applicable	75
Ferrannini 2010	Placebo; None; Oral	Weight change	kg	88.8	19	Not applicable	Not applicable	Not applicable	75
Foley 2009	Gliclazide; 80-320 mg daily; Oral	BMI change	kg/m2	30.6	5	Not applicable	Not applicable	Not applicable	546
Foley 2009	Gliclazide; 80-320 mg daily; Oral	HbA1c change	%	8.6	1	Not applicable	Not applicable	Not applicable	546
Foley 2009	Gliclazide; 80-320 mg daily; Oral	Weight change	kg	84.2	16.3	Not applicable	Not applicable	Not applicable	546

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Foley 2009	Vildagliptin; 100 mg daily; Oral	BMI change	kg/m2	30.8	5.5	Not applicable	Not applicable	Not applicable	546
Foley 2009	Vildagliptin; 100 mg daily; Oral	HbA1c change	%	8.7	1.1	Not applicable	Not applicable	Not applicable	546
Foley 2009	Vildagliptin; 100 mg daily; Oral	Weight change	kg	84.3	17.6	Not applicable	Not applicable	Not applicable	546
Foley 2011	Placebo; None; Oral	HbA1c change	%	6	0.7	Not applicable	Not applicable	Not applicable	30
Foley 2011	Vildagliptin; 100 mg daily; Oral	HbA1c change	%	6	0.7	Not applicable	Not applicable	Not applicable	29
Frederich 2012	Placebo; None; Oral	BMI change	kg/m2	31.1	4.54	Not applicable	Not applicable	Not applicable	74
Frederich 2012	Placebo; None; Oral	HbA1c change	%	7.8	1	Not applicable	Not applicable	Not applicable	74
Frederich 2012	Placebo; None; Oral	Weight change	kg	85.4	14.4	Not applicable	Not applicable	Not applicable	74
Frederich 2012	Saxagliptin; 2.5 mg daily; Oral	BMI change	kg/m2	30.4	4.84	Not applicable	Not applicable	Not applicable	74
Frederich 2012	Saxagliptin; 2.5 mg daily; Oral	HbA1c change	%	8	0.8	Not applicable	Not applicable	Not applicable	74

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Frederich 2012	Saxagliptin; 2.5 mg daily; Oral	Weight change	kg	83.8	16.7	Not applicable	Not applicable	Not applicable	74
Frederich 2012	Saxagliptin; 2.5-5 mg daily combined; Oral	BMI change	kg/m2	30.4	5.07	Not applicable	Not applicable	Not applicable	291
Frederich 2012	Saxagliptin; 2.5-5 mg daily combined; Oral	HbA1c change	%	7.98	0.93	Not applicable	Not applicable	Not applicable	291
Frederich 2012	Saxagliptin; 2.5-5 mg daily combined; Oral	Weight change	kg	84.75	18.56	Not applicable	Not applicable	Not applicable	291
Frederich 2012	Saxagliptin; 2.5-5 mg daily; Oral	BMI change	kg/m2	30.6	4.72	Not applicable	Not applicable	Not applicable	71
Frederich 2012	Saxagliptin; 2.5-5 mg daily; Oral	HbA1c change	%	8	1.1	Not applicable	Not applicable	Not applicable	71
Frederich 2012	Saxagliptin; 2.5-5 mg daily; Oral	Weight change	kg	85.4	17.25	Not applicable	Not applicable	Not applicable	71

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Frederich 2012	Saxagliptin; 5 mg daily B; Oral	BMI change	kg/m2	29.6	5.37	Not applicable	Not applicable	Not applicable	72
Frederich 2012	Saxagliptin; 5 mg daily B; Oral	HbA1c change	%	7.9	0.9	Not applicable	Not applicable	Not applicable	72
Frederich 2012	Saxagliptin; 5 mg daily B; Oral	Weight change	kg	83.3	19.1	Not applicable	Not applicable	Not applicable	72
Frederich 2012	Saxagliptin; 5 mg daily; Oral	BMI change	kg/m2	31	5.23	Not applicable	Not applicable	Not applicable	74
Frederich 2012	Saxagliptin; 5 mg daily; Oral	HbA1c change	%	8	0.9	Not applicable	Not applicable	Not applicable	74
Frederich 2012	Saxagliptin; 5 mg daily; Oral	Weight change	kg	86.5	20.71	Not applicable	Not applicable	Not applicable	74
Gantz 2017D	Omarigliptin; 25 mg daily; Oral	BMI change	kg/m2	25.2	3.7	Not applicable	Not applicable	Not applicable	166
Gantz 2017D	Omarigliptin; 25 mg daily; Oral	HbA1c change	%	7.9	0.7	Not applicable	Not applicable	Not applicable	166
Gantz 2017D	Omarigliptin; 25 mg daily; Oral	Weight change	kg	67	13	Not applicable	Not applicable	Not applicable	166

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Gantz 2017D	Placebo; None; Oral	BMI change	kg/m2	24.3	3.3	Not applicable	Not applicable	Not applicable	83
Gantz 2017D	Placebo; None; Oral	HbA1c change	%	8.1	0.7	Not applicable	Not applicable	Not applicable	83
Gantz 2017D	Placebo; None; Oral	Weight change	kg	64	12	Not applicable	Not applicable	Not applicable	83
Gantz 2017D	Sitagliptin; 50 mg daily; Oral	BMI change	kg/m2	25.4	4.2	Not applicable	Not applicable	Not applicable	165
Gantz 2017D	Sitagliptin; 50 mg daily; Oral	HbA1c change	%	8	0.8	Not applicable	Not applicable	Not applicable	165
Gantz 2017D	Sitagliptin; 50 mg daily; Oral	Weight change	kg	69	14	Not applicable	Not applicable	Not applicable	165
Goldstein 2007	Metformin type unspecified; 1000 mg daily; Oral	BMI change	kg/m2	32.1	6.8	Not applicable	Not applicable	Not applicable	178
Goldstein 2007	Metformin type unspecified; 1000 mg daily; Oral	HbA1c change	%	8.9	1	Not applicable	Not applicable	Not applicable	178
Goldstein 2007	Metformin type unspecified; 1000-2000	BMI change	kg/m2	32.15	6.95	Not applicable	Not applicable	Not applicable	364

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	mg daily combined; Oral								
Goldstein 2007	Metformin type unspecified; 1000-2000 mg daily combined; Oral	HbA1c change	%	8.79	0.96	Not applicable	Not applicable	Not applicable	364
Goldstein 2007	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	32.2	7.1	Not applicable	Not applicable	Not applicable	177
Goldstein 2007	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	8.68	0.91	Not applicable	Not applicable	Not applicable	177
Goldstein 2007	Placebo; None; Oral	BMI change	kg/m2	32.5	6.7	Not applicable	Not applicable	Not applicable	176
Goldstein 2007	Placebo; None; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	176
Goldstein 2007	Sitagliptin + Metformin; 50 mg + 1000 mg daily; Oral	BMI change	kg/m2	32.1	6.7	Not applicable	Not applicable	Not applicable	183

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Goldstein 2007	Sitagliptin + Metformin; 50 mg + 1000 mg daily; Oral	HbA1c change	%	8.79	1	Not applicable	Not applicable	Not applicable	183
Goldstein 2007	Sitagliptin + Metformin; 50 mg + 1000/2000 mg daily combined; Oral	BMI change	kg/m2	32.25	6.65	Not applicable	Not applicable	Not applicable	372
Goldstein 2007	Sitagliptin + Metformin; 50 mg + 1000/2000 mg daily combined; Oral	HbA1c change	%	8.78	1	Not applicable	Not applicable	Not applicable	372
Goldstein 2007	Sitagliptin + Metformin; 50 mg + 2000 mg daily; Oral	BMI change	kg/m2	32.4	6.6	Not applicable	Not applicable	Not applicable	178
Goldstein 2007	Sitagliptin + Metformin; 50 mg + 2000 mg daily; Oral	HbA1c change	%	8.76	1	Not applicable	Not applicable	Not applicable	178

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Goldstein 2007	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	31.2	5.9	Not applicable	Not applicable	Not applicable	179
Goldstein 2007	Sitagliptin; 100 mg daily; Oral	HbA1c change	%	8.9	1	Not applicable	Not applicable	Not applicable	179
Guo 2014	Metformin type unspecified; 500-2000 mg daily; Oral	HbA1c change	%	7.82	0.82	Not applicable	Not applicable	Not applicable	29
Guo 2014	Placebo; 500-2000 mg daily; Oral	HbA1c change	%	8.01	0.59	Not applicable	Not applicable	Not applicable	29
Haak 2012	Linagliptin + Metformin; 2.5 mg + 1000 mg daily; Oral	BMI change	kg/m2	29.7	5.3	Not applicable	Not applicable	Not applicable	143
Haak 2012	Linagliptin + Metformin; 2.5 mg + 1000 mg daily; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	143
Haak 2012	Linagliptin + Metformin; 2.5 mg + 1000 mg daily; Oral	Weight change	kg	80.8	19	Not applicable	Not applicable	Not applicable	143

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Haak 2012	Linagliptin + Metformin; 2.5 mg + 1000-2000 mg daily combined; Oral	BMI change	kg/m2	28.8	4.75	Not applicable	Not applicable	Not applicable	286
Haak 2012	Linagliptin + Metformin; 2.5 mg + 1000-2000 mg daily combined; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	286
Haak 2012	Linagliptin + Metformin; 2.5 mg + 1000-2000 mg daily combined; Oral	Weight change	kg	78.34	17.37	Not applicable	Not applicable	Not applicable	286
Haak 2012	Linagliptin + Metformin; 2.5 mg + 2000 mg daily; Oral	BMI change	kg/m2	28.6	4.8	Not applicable	Not applicable	Not applicable	143
Haak 2012	Linagliptin + Metformin; 2.5 mg +	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	143

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	2000 mg daily; Oral								
Haak 2012	Linagliptin + Metformin; 2.5 mg + 2000 mg daily; Oral	Weight change	kg	76.7	16	Not applicable	Not applicable	Not applicable	143
Haak 2012	Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	29	4.7	Not applicable	Not applicable	Not applicable	142
Haak 2012	Linagliptin; 5 mg daily; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	142
Haak 2012	Linagliptin; 5 mg daily; Oral	Weight change	kg	80	18.5	Not applicable	Not applicable	Not applicable	142
Haak 2012	Metformin type unspecified; 1000 mg daily; Oral	BMI change	kg/m2	28.9	5.3	Not applicable	Not applicable	Not applicable	144
Haak 2012	Metformin type unspecified; 1000 mg daily; Oral	HbA1c change	%	8.7	0.9	Not applicable	Not applicable	Not applicable	144
Haak 2012	Metformin type unspecified;	Weight change	kg	79.9	18.4	Not applicable	Not applicable	Not applicable	144

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	1000 mg daily; Oral								
Haak 2012	Metformin type unspecified; 1000-2000 mg daily combined; Oral	BMI change	kg/m2	29.2	5.31	Not applicable	Not applicable	Not applicable	291
Haak 2012	Metformin type unspecified; 1000-2000 mg daily combined; Oral	HbA1c change	%	8.6	0.91	Not applicable	Not applicable	Not applicable	291
Haak 2012	Metformin type unspecified; 1000-2000 mg daily combined; Oral	Weight change	kg	79.95	18.45	Not applicable	Not applicable	Not applicable	291
Haak 2012	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	29.5	5.3	Not applicable	Not applicable	Not applicable	147
Haak 2012	Metformin type	HbA1c change	%	8.5	0.9	Not applicable	Not applicable	Not applicable	147

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	unspecified; 2000 mg daily; Oral								
Haak 2012	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	80	18.5	Not applicable	Not applicable	Not applicable	147
Haak 2012	Placebo; None; Oral	BMI change	kg/m2	28.6	5.2	Not applicable	Not applicable	Not applicable	72
Haak 2012	Placebo; None; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	72
Haak 2012	Placebo; None; Oral	Weight change	kg	76.8	17.5	Not applicable	Not applicable	Not applicable	72
Hadjadj 2016	Empagliflozin + Metformin; 10 mg + 1000 mg daily; Oral	BMI change	kg/m2	30.1	5.3	Not applicable	Not applicable	Not applicable	161
Hadjadj 2016	Empagliflozin + Metformin; 10 mg + 1000 mg daily; Oral	HbA1c change	%	8.68	1.26	Not applicable	Not applicable	Not applicable	161
Hadjadj 2016	Empagliflozin + Metformin; 10 mg + 1000 mg daily; Oral	Weight change	kg	82.3	19.2	Not applicable	Not applicable	Not applicable	161

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Hadjadj 2016	Empagliflozin + Metformin; 10 mg + 2000 mg daily; Oral	BMI change	kg/m2	30.5	5	Not applicable	Not applicable	Not applicable	167
Hadjadj 2016	Empagliflozin + Metformin; 10 mg + 2000 mg daily; Oral	HbA1c change	%	8.65	1.23	Not applicable	Not applicable	Not applicable	167
Hadjadj 2016	Empagliflozin + Metformin; 10 mg + 2000 mg daily; Oral	Weight change	kg	83	19.1	Not applicable	Not applicable	Not applicable	167
Hadjadj 2016	Empagliflozin + Metformin; 10-25 mg + 1000-2000 mg daily combined; Oral	BMI change	kg/m2	30.3	5.2	Not applicable	Not applicable	Not applicable	680
Hadjadj 2016	Empagliflozin + Metformin; 10-25 mg + 1000-2000 mg daily combined; Oral	HbA1c change	%	8.71	1.24	Not applicable	Not applicable	Not applicable	680

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Hadjadj 2016	Empagliflozin + Metformin; 10-25 mg + 1000-2000 mg daily combined; Oral	Weight change	kg	83	19.2	Not applicable	Not applicable	Not applicable	680
Hadjadj 2016	Empagliflozin + Metformin; 25 mg + 1000 mg daily; Oral	BMI change	kg/m2	30.2	5.2	Not applicable	Not applicable	Not applicable	165
Hadjadj 2016	Empagliflozin + Metformin; 25 mg + 1000 mg daily; Oral	HbA1c change	%	8.84	1.31	Not applicable	Not applicable	Not applicable	165
Hadjadj 2016	Empagliflozin + Metformin; 25 mg + 1000 mg daily; Oral	Weight change	kg	82.9	18.7	Not applicable	Not applicable	Not applicable	165
Hadjadj 2016	Empagliflozin + Metformin; 25 mg + 2000 mg daily; Oral	BMI change	kg/m2	30.4	5.3	Not applicable	Not applicable	Not applicable	169
Hadjadj 2016	Empagliflozin + Metformin;	HbA1c change	%	8.66	1.14	Not applicable	Not applicable	Not applicable	169

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	25 mg + 2000 mg daily; Oral								
Hadjadj 2016	Empagliflozin + Metformin; 25 mg + 2000 mg daily; Oral	Weight change	kg	83.8	19.8	Not applicable	Not applicable	Not applicable	169
Hadjadj 2016	Empagliflozin ; 10 mg daily; Oral	BMI change	kg/m2	30.6	5.9	Not applicable	Not applicable	Not applicable	169
Hadjadj 2016	Empagliflozin ; 10 mg daily; Oral	HbA1c change	%	8.62	1.24	Not applicable	Not applicable	Not applicable	169
Hadjadj 2016	Empagliflozin ; 10 mg daily; Oral	Weight change	kg	83.1	20.3	Not applicable	Not applicable	Not applicable	169
Hadjadj 2016	Empagliflozin ; 10-25 mg daily combined; Oral	BMI change	kg/m2	30.45	5.57	Not applicable	Not applicable	Not applicable	339
Hadjadj 2016	Empagliflozin ; 10-25 mg daily combined; Oral	HbA1c change	%	8.74	1.27	Not applicable	Not applicable	Not applicable	339
Hadjadj 2016	Empagliflozin ; 10-25 mg	Weight change	kg	83.44	20.06	Not applicable	Not applicable	Not applicable	339

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	daily combined; Oral								
Hadjadj 2016	Empagliflozin ; 25 mg daily; Oral	BMI change	kg/m2	30.3	5.2	Not applicable	Not applicable	Not applicable	164
Hadjadj 2016	Empagliflozin ; 25 mg daily; Oral	HbA1c change	%	8.86	1.29	Not applicable	Not applicable	Not applicable	164
Hadjadj 2016	Empagliflozin ; 25 mg daily; Oral	Weight change	kg	83.8	19.8	Not applicable	Not applicable	Not applicable	164
Hadjadj 2016	Metformin type unspecified; 1000 mg daily; Oral	BMI change	kg/m2	30.5	5.9	Not applicable	Not applicable	Not applicable	168
Hadjadj 2016	Metformin type unspecified; 1000 mg daily; Oral	HbA1c change	%	8.69	1.04	Not applicable	Not applicable	Not applicable	168
Hadjadj 2016	Metformin type unspecified; 1000 mg daily; Oral	Weight change	kg	83.7	20.1	Not applicable	Not applicable	Not applicable	168
Hadjadj 2016	Metformin type	BMI change	kg/m2	30.4	5.85	Not applicable	Not applicable	Not applicable	341

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	unspecified; 1000-2000 mg daily combined; Oral								
Hadjadj 2016	Metformin type unspecified; 1000-2000 mg daily combined; Oral	HbA1c change	%	8.64	1.09	Not applicable	Not applicable	Not applicable	341
Hadjadj 2016	Metformin type unspecified; 1000-2000 mg daily combined; Oral	Weight change	kg	83.21	20.66	Not applicable	Not applicable	Not applicable	341
Hadjadj 2016	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	30.3	5.8	Not applicable	Not applicable	Not applicable	164
Hadjadj 2016	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	8.59	1.13	Not applicable	Not applicable	Not applicable	164

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Hadjadj 2016	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	82.7	21.2	Not applicable	Not applicable	Not applicable	164
Hällsten 2002	Metformin type unspecified; 1000-2000 mg daily; Oral	HbA1c change	%	6.9	0.72	0.2	Not applicable	Not applicable	13
Hällsten 2002	Metformin type unspecified; 1000-2000 mg daily; Oral	Weight change	kg	88.8	10.82	3	Not applicable	Not applicable	13
Hällsten 2002	Placebo; None; Oral	HbA1c change	%	6.3	0.37	0.1	Not applicable	Not applicable	14
Hällsten 2002	Placebo; None; Oral	Weight change	kg	88.3	9.35	2.5	Not applicable	Not applicable	14
Hartley 2015	Glimepiride; 1-6 mg daily; Oral	HbA1c change	%	7.8	0.7	Not applicable	Not applicable	Not applicable	191
Hartley 2015	Glimepiride; 1-6 mg daily; Oral	Weight change	kg	75.3	16.3	Not applicable	Not applicable	Not applicable	191

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Hartley 2015	Sitagliptin; 50-100 mg daily; Oral	HbA1c change	%	7.8	0.7	Not applicable	Not applicable	Not applicable	197
Hartley 2015	Sitagliptin; 50-100 mg daily; Oral	Weight change	kg	76.9	15.1	Not applicable	Not applicable	Not applicable	197
Henry 2012A	Dapagliflozin + Metformin; 5 mg + 500-2000 mg daily; Oral	HbA1c change	%	9.2	1.3	Not applicable	Not applicable	Not applicable	194
Henry 2012A	Dapagliflozin + Metformin; 5 mg + 500-2000 mg daily; Oral	Weight change	kg	84.24	19.51	Not applicable	Not applicable	Not applicable	194
Henry 2012A	Dapagliflozin; 5 mg daily; Oral	HbA1c change	%	9.1	1.4	Not applicable	Not applicable	Not applicable	203
Henry 2012A	Dapagliflozin; 5 mg daily; Oral	Weight change	kg	86.2	21.13	Not applicable	Not applicable	Not applicable	203
Henry 2012A	Metformin type unspecified; 500-2000 mg daily combined; Oral	HbA1c change	%	9.2	1.3	Not applicable	Not applicable	Not applicable	201

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Henry 2012A	Metformin type unspecified; 500-2000 mg daily combined; Oral	Weight change	kg	85.7	19.9	Not applicable	Not applicable	Not applicable	201
Henry 2012B	Dapagliflozin + Metformin; 5 mg + 500-2000 mg daily; Oral	HbA1c change	%	9.1	1.3	Not applicable	Not applicable	Not applicable	211
Henry 2012B	Dapagliflozin + Metformin; 5 mg + 500-2000 mg daily; Oral	Weight change	kg	88.56	19.72	Not applicable	Not applicable	Not applicable	211
Henry 2012B	Dapagliflozin; 10 mg daily; Oral	HbA1c change	%	9.1	1.3	Not applicable	Not applicable	Not applicable	219
Henry 2012B	Dapagliflozin; 10 mg daily; Oral	Weight change	kg	88.53	19.33	Not applicable	Not applicable	Not applicable	219
Henry 2012B	Metformin type unspecified; 500-2000 mg daily	HbA1c change	%	9.1	1.3	Not applicable	Not applicable	Not applicable	208

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	combined; Oral								
Henry 2012B	Metformin type unspecified; 500-2000 mg daily combined; Oral	Weight change	kg	87.2	19.4	Not applicable	Not applicable	Not applicable	208
Henry 2014	Pioglitazone + Sitagliptin; 15 mg + 100 mg daily; Oral	BMI change	kg/m2	30.7	5.4	Not applicable	Not applicable	Not applicable	193
Henry 2014	Pioglitazone + Sitagliptin; 15 mg + 100 mg daily; Oral	HbA1c change	%	8.8	1.1	Not applicable	Not applicable	Not applicable	179
Henry 2014	Pioglitazone + Sitagliptin; 15 mg + 100 mg daily; Oral	Weight change	kg	84.5	19.8	Not applicable	Not applicable	Not applicable	120
Henry 2014	Pioglitazone + Sitagliptin; 15-45 mg + 100 mg daily combined; Oral	BMI change	kg/m2	30.8	5.4	Not applicable	Not applicable	Not applicable	581

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Henry 2014	Pioglitazone + Sitagliptin; 15-45 mg + 100 mg daily combined; Oral	HbA1c change	%	8.8	1.1	Not applicable	Not applicable	Not applicable	581
Henry 2014	Pioglitazone + Sitagliptin; 15-45 mg + 100 mg daily combined; Oral	Weight change	kg	86.27	20.48	Not applicable	Not applicable	Not applicable	358
Henry 2014	Pioglitazone + Sitagliptin; 30 mg + 100 mg daily; Oral	BMI change	kg/m2	31.1	5.8	Not applicable	Not applicable	Not applicable	190
Henry 2014	Pioglitazone + Sitagliptin; 30 mg + 100 mg daily; Oral	HbA1c change	%	8.7	1.1	Not applicable	Not applicable	Not applicable	173
Henry 2014	Pioglitazone + Sitagliptin; 30 mg + 100 mg daily; Oral	Weight change	kg	88.1	21.9	Not applicable	Not applicable	Not applicable	115
Henry 2014	Pioglitazone + Sitagliptin;	BMI change	kg/m2	30.5	4.9	Not applicable	Not applicable	Not applicable	198

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	45 mg + 100 mg daily; Oral								
Henry 2014	Pioglitazone + Sitagliptin; 45 mg + 100 mg daily; Oral	HbA1c change	%	8.9	1.1	Not applicable	Not applicable	Not applicable	188
Henry 2014	Pioglitazone + Sitagliptin; 45 mg + 100 mg daily; Oral	Weight change	kg	86.3	19.6	Not applicable	Not applicable	Not applicable	123
Henry 2014	Pioglitazone; 15 mg daily; Oral	BMI change	kg/m2	31.4	5.7	Not applicable	Not applicable	Not applicable	183
Henry 2014	Pioglitazone; 15 mg daily; Oral	HbA1c change	%	8.8	1	Not applicable	Not applicable	Not applicable	163
Henry 2014	Pioglitazone; 15 mg daily; Oral	Weight change	kg	90.4	20.3	Not applicable	Not applicable	Not applicable	86
Henry 2014	Pioglitazone; 15-45 mg daily combined; Oral	BMI change	kg/m2	30.9	5.3	Not applicable	Not applicable	Not applicable	565
Henry 2014	Pioglitazone; 15-45 mg	HbA1c change	%	8.9	1.1	Not applicable	Not applicable	Not applicable	565

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	daily combined; Oral								
Henry 2014	Pioglitazone; 15-45 mg daily combined; Oral	Weight change	kg	87.19	20.06	Not applicable	Not applicable	Not applicable	308
Henry 2014	Pioglitazone; 30 mg daily; Oral	BMI change	kg/m2	30.9	5.6	Not applicable	Not applicable	Not applicable	194
Henry 2014	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	8.9	1.1	Not applicable	Not applicable	Not applicable	181
Henry 2014	Pioglitazone; 30 mg daily; Oral	Weight change	kg	83.4	19.1	Not applicable	Not applicable	Not applicable	111
Henry 2014	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	31.2	5.1	Not applicable	Not applicable	Not applicable	188
Henry 2014	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	8.7	1.2	Not applicable	Not applicable	Not applicable	171
Henry 2014	Pioglitazone; 45 mg daily; Oral	Weight change	kg	88.5	20.2	Not applicable	Not applicable	Not applicable	111
Henry 2014	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	31.4	5.7	Not applicable	Not applicable	Not applicable	186

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Henry 2014	Sitagliptin; 100 mg daily; Oral	HbA1c change	%	8.6	1.2	Not applicable	Not applicable	Not applicable	172
Henry 2014	Sitagliptin; 100 mg daily; Oral	Weight change	kg	88.1	18.8	Not applicable	Not applicable	Not applicable	101
Horton 2000	Metformin type unspecified; 1500 mg daily; Oral	BMI change	kg/m2	29.6	4.3	Not applicable	Not applicable	Not applicable	178
Horton 2000	Metformin type unspecified; 1500 mg daily; Oral	HbA1c change	%	8.4	1.2	Not applicable	Not applicable	Not applicable	178
Horton 2000	Placebo; None; Oral	BMI change	kg/m2	29.2	3.9	Not applicable	Not applicable	Not applicable	172
Horton 2000	Placebo; None; Oral	HbA1c change	%	8.3	1.1	Not applicable	Not applicable	Not applicable	172
Inagaki 2014	Canagliflozin; 100 mg daily; Oral	BMI change	kg/m2	25.59	4.2	Not applicable	Not applicable	Not applicable	90
Inagaki 2014	Canagliflozin; 100 mg daily; Oral	HbA1c change	%	7.98	0.73	Not applicable	Not applicable	Not applicable	90

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Inagaki 2014	Canagliflozin; 100 mg daily; Oral	Weight change	kg	69.1	14.48	Not applicable	Not applicable	Not applicable	90
Inagaki 2014	Canagliflozin; 100-200 mg daily combined; Oral	BMI change	kg/m2	25.51	4.19	Not applicable	Not applicable	Not applicable	179
Inagaki 2014	Canagliflozin; 100-200 mg daily combined; Oral	HbA1c change	%	8.01	0.75	Not applicable	Not applicable	Not applicable	179
Inagaki 2014	Canagliflozin; 100-200 mg daily combined; Oral	Weight change	kg	69.49	14.31	Not applicable	Not applicable	Not applicable	179
Inagaki 2014	Canagliflozin; 200 mg daily; Oral	BMI change	kg/m2	25.43	4.18	Not applicable	Not applicable	Not applicable	89
Inagaki 2014	Canagliflozin; 200 mg daily; Oral	HbA1c change	%	8.04	0.77	Not applicable	Not applicable	Not applicable	89
Inagaki 2014	Canagliflozin; 200 mg daily; Oral	Weight change	kg	69.88	14.22	Not applicable	Not applicable	Not applicable	89
Inagaki 2014	Placebo; None; Oral	BMI change	kg/m2	25.85	4.39	Not applicable	Not applicable	Not applicable	93

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Inagaki 2014	Placebo; None; Oral	HbA1c change	%	8.04	0.7	Not applicable	Not applicable	Not applicable	93
Inagaki 2014	Placebo; None; Oral	Weight change	kg	68.57	15.15	Not applicable	Not applicable	Not applicable	93
Inagaki 2022	Dulaglutide; 0.75 mg weekly; Subcutaneous	BMI change	kg/m2	27.8	3.7	Not applicable	Not applicable	Not applicable	159
Inagaki 2022	Dulaglutide; 0.75 mg weekly; Subcutaneous	HbA1c change	%	8.2	0.9	Not applicable	Not applicable	Not applicable	159
Inagaki 2022	Dulaglutide; 0.75 mg weekly; Subcutaneous	Weight change	kg	76.5	13.2	Not applicable	Not applicable	Not applicable	159
Inagaki 2022	Tirzepatide; 10 mg weekly; Subcutaneous	BMI change	kg/m2	28	4.1	Not applicable	Not applicable	Not applicable	158
Inagaki 2022	Tirzepatide; 10 mg weekly; Subcutaneous	HbA1c change	%	8.2	0.9	Not applicable	Not applicable	Not applicable	158

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Inagaki 2022	Tirzepatide; 10 mg weekly; Subcutaneous	Weight change	kg	78.9	13.7	Not applicable	Not applicable	Not applicable	158
Inagaki 2022	Tirzepatide; 15 mg weekly; Subcutaneous	BMI change	kg/m2	28.1	4.4	Not applicable	Not applicable	Not applicable	160
Inagaki 2022	Tirzepatide; 15 mg weekly; Subcutaneous	HbA1c change	%	8.2	0.9	Not applicable	Not applicable	Not applicable	160
Inagaki 2022	Tirzepatide; 15 mg weekly; Subcutaneous	Weight change	kg	78.9	14.3	Not applicable	Not applicable	Not applicable	160
Inagaki 2022	Tirzepatide; 5 mg weekly; Subcutaneous	BMI change	kg/m2	28.6	5.4	Not applicable	Not applicable	Not applicable	159
Inagaki 2022	Tirzepatide; 5 mg weekly; Subcutaneous	HbA1c change	%	8.2	0.9	Not applicable	Not applicable	Not applicable	159

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Inagaki 2022	Tirzepatide; 5 mg weekly; Subcutaneous	Weight change	kg	78.5	16.3	Not applicable	Not applicable	Not applicable	159
Inagaki 2022	Tirzepatide; 5-15 mg weekly combined; Subcutaneous	BMI change	kg/m2	28.23	4.66	Not applicable	Not applicable	Not applicable	477
Inagaki 2022	Tirzepatide; 5-15 mg weekly combined; Subcutaneous	HbA1c change	%	8.2	0.9	Not applicable	Not applicable	Not applicable	477
Inagaki 2022	Tirzepatide; 5-15 mg weekly combined; Subcutaneous	Weight change	kg	78.77	14.78	Not applicable	Not applicable	Not applicable	477
Ji 2014	Dapagliflozin; 10 mg daily; Oral	BMI change	kg/m2	25.93	3.64	Not applicable	Not applicable	Not applicable	132
Ji 2014	Dapagliflozin; 10 mg daily; Oral	HbA1c change	%	8.28	0.95	Not applicable	Not applicable	Not applicable	133

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Ji 2014	Dapagliflozin; 10 mg daily; Oral	Weight change	kg	72.18	13.23	Not applicable	Not applicable	Not applicable	132
Ji 2014	Dapagliflozin; 5 mg daily; Oral	HbA1c change	%	8.14	0.74	Not applicable	Not applicable	Not applicable	128
Ji 2014	Dapagliflozin; 5-10 mg daily combined; Oral	BMI change	kg/m2	25.47	3.37	Not applicable	Not applicable	Not applicable	261
Ji 2014	Dapagliflozin; 5-10 mg daily combined; Oral	HbA1c change	%	8.21	0.86	Not applicable	Not applicable	Not applicable	261
Ji 2014	Dapagliflozin; 5-10 mg daily combined; Oral	Weight change	kg	69.92	11.58	Not applicable	Not applicable	Not applicable	261
Ji 2014	Placebo; None; Oral	HbA1c change	%	8.35	0.95	Not applicable	Not applicable	Not applicable	132
Ji 2016A	Metformin type unspecified; 1000 mg daily; Oral	BMI change	kg/m2	26	3.7	Not applicable	Not applicable	Not applicable	126
Ji 2016A	Metformin type unspecified;	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	116

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	1000 mg daily; Oral								
Ji 2016A	Metformin type unspecified; 1000 mg daily; Oral	Weight change	kg	71.1	13.7	Not applicable	Not applicable	Not applicable	126
Ji 2016A	Metformin type unspecified; 1000-1700 mg daily combined; Oral	BMI change	kg/m2	25.9	3.6	Not applicable	Not applicable	Not applicable	250
Ji 2016A	Metformin type unspecified; 1000-1700 mg daily combined; Oral	HbA1c change	%	8.7	1.05	Not applicable	Not applicable	Not applicable	233
Ji 2016A	Metformin type unspecified; 1000-1700 mg daily combined; Oral	Weight change	kg	71.1	12.79	Not applicable	Not applicable	Not applicable	250
Ji 2016A	Metformin type	BMI change	kg/m2	25.8	3.5	Not applicable	Not applicable	Not applicable	124

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	unspecified; 1700 mg daily; Oral								
Ji 2016A	Metformin type unspecified; 1700 mg daily; Oral	HbA1c change	%	8.7	1.1	Not applicable	Not applicable	Not applicable	117
Ji 2016A	Metformin type unspecified; 1700 mg daily; Oral	Weight change	kg	71.1	11.8	Not applicable	Not applicable	Not applicable	124
Ji 2016A	Placebo; None; Oral	BMI change	kg/m2	25.4	3.4	Not applicable	Not applicable	Not applicable	127
Ji 2016A	Placebo; None; Oral	HbA1c change	%	9	1.1	Not applicable	Not applicable	Not applicable	117
Ji 2016A	Placebo; None; Oral	Weight change	kg	70.8	12.5	Not applicable	Not applicable	Not applicable	127
Ji 2016A	Sitagliptin + Metformin; 100 mg + 1000 mg daily; Oral	BMI change	kg/m2	26.1	3.4	Not applicable	Not applicable	Not applicable	122
Ji 2016A	Sitagliptin + Metformin; 100 mg + 1000 mg daily; Oral	HbA1c change	%	8.5	1	Not applicable	Not applicable	Not applicable	118

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Ji 2016A	Sitagliptin + Metformin; 100 mg + 1000 mg daily; Oral	Weight change	kg	72.4	12.1	Not applicable	Not applicable	Not applicable	122
Ji 2016A	Sitagliptin + Metformin; 100 mg + 1000-1700 mg daily combined; Oral	BMI change	kg/m2	25.75	3.27	Not applicable	Not applicable	Not applicable	247
Ji 2016A	Sitagliptin + Metformin; 100 mg + 1000-1700 mg daily combined; Oral	HbA1c change	%	8.55	0.95	Not applicable	Not applicable	Not applicable	232
Ji 2016A	Sitagliptin + Metformin; 100 mg + 1000-1700 mg daily combined; Oral	Weight change	kg	70.88	11.56	Not applicable	Not applicable	Not applicable	247
Ji 2016A	Sitagliptin + Metformin; 100 mg +	BMI change	kg/m2	25.4	3.1	Not applicable	Not applicable	Not applicable	125

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	1700 mg daily; Oral								
Ji 2016A	Sitagliptin + Metformin; 100 mg + 1700 mg daily; Oral	HbA1c change	%	8.6	0.9	Not applicable	Not applicable	Not applicable	114
Ji 2016A	Sitagliptin + Metformin; 100 mg + 1700 mg daily; Oral	Weight change	kg	69.4	10.8	Not applicable	Not applicable	Not applicable	125
Ji 2016A	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	26	3.5	Not applicable	Not applicable	Not applicable	120
Ji 2016A	Sitagliptin; 100 mg daily; Oral	HbA1c change	%	8.7	1.1	Not applicable	Not applicable	Not applicable	113
Ji 2016A	Sitagliptin; 100 mg daily; Oral	Weight change	kg	71.8	12.1	Not applicable	Not applicable	Not applicable	120
Ji 2017	Alogliptin + Metformin; 25 mg + 1000 mg daily; Oral	BMI change	kg/m2	26.56	4.22	Not applicable	Not applicable	Not applicable	159
Ji 2017	Alogliptin + Metformin; 25 mg +	HbA1c change	%	8.39	0.81	Not applicable	Not applicable	Not applicable	159

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	1000 mg daily; Oral								
Ji 2017	Alogliptin; 25 mg daily; Oral	BMI change	kg/m2	26.3	3.57	Not applicable	Not applicable	Not applicable	163
Ji 2017	Alogliptin; 25 mg daily; Oral	HbA1c change	%	8.48	0.71	Not applicable	Not applicable	Not applicable	163
Ji 2017	Metformin type unspecified; 1000 mg daily; Oral	BMI change	kg/m2	26.16	3.92	Not applicable	Not applicable	Not applicable	162
Ji 2017	Metformin type unspecified; 1000 mg daily; Oral	HbA1c change	%	8.4	0.78	Not applicable	Not applicable	Not applicable	162
Ji 2017	Placebo; None; Oral	BMI change	kg/m2	26.16	3.51	Not applicable	Not applicable	Not applicable	163
Ji 2017	Placebo; None; Oral	HbA1c change	%	8.21	0.77	Not applicable	Not applicable	Not applicable	163
Jiang 2021	Dapagliflozin; 10 mg daily; Oral	BMI change	kg/m2	26.6	1.32	Not applicable	Not applicable	Not applicable	19
Jiang 2021	Dapagliflozin; 10 mg daily; Oral	Weight change	kg	71.97	8.31	Not applicable	Not applicable	Not applicable	19

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Jiang 2021	Placebo; None; Oral	BMI change	kg/m2	25.64	1.41	Not applicable	Not applicable	Not applicable	10
Jiang 2021	Placebo; None; Oral	Weight change	kg	66.2	1.93	Not applicable	Not applicable	Not applicable	10
Kahl 2019	Empagliflozin ; 25 mg daily; Oral	BMI change	kg/m2	32.1	4.6	Not applicable	Not applicable	Not applicable	42
Kahl 2019	Empagliflozin ; 25 mg daily; Oral	HbA1c change	%	6.8	0.5	Not applicable	Not applicable	Not applicable	42
Kahl 2019	Empagliflozin ; 25 mg daily; Oral	Weight change	kg	94.7	15.79	2.42	90	99.5	42
Kahl 2019	Placebo; None; Oral	BMI change	kg/m2	32.4	4.2	Not applicable	Not applicable	Not applicable	42
Kahl 2019	Placebo; None; Oral	HbA1c change	%	6.7	0.7	Not applicable	Not applicable	Not applicable	42
Kahl 2019	Placebo; None; Oral	Weight change	kg	98	19.28	2.96	92.2	103.8	42
Kaku 2014	Dapagliflozin; 10 mg daily; Oral	BMI change	kg/m2	26.06	4.52	Not applicable	Not applicable	Not applicable	88
Kaku 2014	Dapagliflozin; 10 mg daily; Oral	HbA1c change	%	7.46	0.61	Not applicable	Not applicable	Not applicable	88
Kaku 2014	Dapagliflozin; 10 mg daily; Oral	Weight change	kg	69.7	13.82	Not applicable	Not applicable	Not applicable	88

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Kaku 2014	Dapagliflozin; 5 mg daily; Oral	BMI change	kg/m2	24.88	3.91	Not applicable	Not applicable	Not applicable	86
Kaku 2014	Dapagliflozin; 5 mg daily; Oral	HbA1c change	%	7.5	0.72	Not applicable	Not applicable	Not applicable	86
Kaku 2014	Dapagliflozin; 5 mg daily; Oral	Weight change	kg	65.81	14.37	Not applicable	Not applicable	Not applicable	86
Kaku 2014	Dapagliflozin; 5-10 mg daily combined; Oral	BMI change	kg/m2	24.48	4.26	Not applicable	Not applicable	Not applicable	174
Kaku 2014	Dapagliflozin; 5-10 mg daily combined; Oral	HbA1c change	%	7.48	0.67	Not applicable	Not applicable	Not applicable	174
Kaku 2014	Dapagliflozin; 5-10 mg daily combined; Oral	Weight change	kg	67.78	14.19	Not applicable	Not applicable	Not applicable	174
Kaku 2014	Placebo; None; Oral	BMI change	kg/m2	25.22	4.39	Not applicable	Not applicable	Not applicable	87
Kaku 2014	Placebo; None; Oral	HbA1c change	%	7.5	0.63	Not applicable	Not applicable	Not applicable	87
Kaku 2014	Placebo; None; Oral	Weight change	kg	65.96	12.91	Not applicable	Not applicable	Not applicable	87

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Kaku 2018A	Empagliflozin + Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	24.9	4	Not applicable	Not applicable	Not applicable	107
Kaku 2018A	Empagliflozin + Linagliptin; 5 mg daily; Oral	HbA1c change	%	8.34	0.54	Not applicable	Not applicable	Not applicable	107
Kaku 2018A	Empagliflozin + Linagliptin; 5 mg daily; Oral	Weight change	kg	69	13	Not applicable	Not applicable	Not applicable	107
Kaku 2018A	Empagliflozin ; 10 mg daily; Oral	BMI change	kg/m2	25.1	3.6	Not applicable	Not applicable	Not applicable	108
Kaku 2018A	Empagliflozin ; 10 mg daily; Oral	HbA1c change	%	8.4	0.68	Not applicable	Not applicable	Not applicable	108
Kaku 2018A	Empagliflozin ; 10 mg daily; Oral	Weight change	kg	70.2	12	Not applicable	Not applicable	Not applicable	108
Kaku 2018B	Empagliflozin + Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	25	4.3	Not applicable	Not applicable	Not applicable	116
Kaku 2018B	Empagliflozin + Linagliptin; 5 mg daily; Oral	HbA1c change	%	8.27	0.59	Not applicable	Not applicable	Not applicable	116

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Kaku 2018B	Empagliflozin + Linagliptin; 5 mg daily; Oral	Weight change	kg	69.1	14.2	Not applicable	Not applicable	Not applicable	116
Kaku 2018B	Empagliflozin ; 25 mg daily; Oral	BMI change	kg/m2	24.7	3.7	Not applicable	Not applicable	Not applicable	116
Kaku 2018B	Empagliflozin ; 25 mg daily; Oral	HbA1c change	%	8.26	0.68	Not applicable	Not applicable	Not applicable	116
Kaku 2018B	Empagliflozin ; 25 mg daily; Oral	Weight change	kg	67.4	13.8	Not applicable	Not applicable	Not applicable	116
Kikuchi 2012	Pioglitazone; 30 mg daily; Oral	BMI change	kg/m2	24.9	3.5	Not applicable	Not applicable	Not applicable	159
Kikuchi 2012	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	8.8	1.3	Not applicable	Not applicable	Not applicable	159
Kikuchi 2012	Placebo; None; Oral	BMI change	kg/m2	25	3.6	Not applicable	Not applicable	Not applicable	54
Kikuchi 2012	Placebo; None; Oral	HbA1c change	%	9	1.4	Not applicable	Not applicable	Not applicable	54
Kim 2017	Glimepiride; 1-6 mg daily; Oral	BMI change	kg/m2	25.2	2.7	Not applicable	Not applicable	Not applicable	147

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Kim 2017	Glimepiride; 1-6 mg daily; Oral	HbA1c change	%	8	0.9	Not applicable	Not applicable	Not applicable	147
Kim 2017	Glimepiride; 1-6 mg daily; Oral	Weight change	kg	67.3	8.8	Not applicable	Not applicable	Not applicable	147
Kim 2017	Sitagliptin + Metformin; 50 mg + 500- 1000 mg daily; Oral	BMI change	kg/m2	25	2.8	Not applicable	Not applicable	Not applicable	145
Kim 2017	Sitagliptin + Metformin; 50 mg + 500- 1000 mg daily; Oral	HbA1c change	%	8.1	0.9	Not applicable	Not applicable	Not applicable	145
Kim 2017	Sitagliptin + Metformin; 50 mg + 500- 1000 mg daily; Oral	Weight change	kg	67.7	10.4	Not applicable	Not applicable	Not applicable	145
Kondo 2016	Glimepiride; 1 mg daily; Oral	BMI change	kg/m2	24.7	3.3	Not applicable	Not applicable	Not applicable	68
Kondo 2016	Glimepiride; 1 mg daily; Oral	HbA1c change	%	7.5	0.5	Not applicable	Not applicable	Not applicable	68

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Kondo 2016	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	24.1	3.8	Not applicable	Not applicable	Not applicable	65
Kondo 2016	Sitagliptin; 100 mg daily; Oral	HbA1c change	%	7.4	0.5	Not applicable	Not applicable	Not applicable	65
Kumar 2014	Placebo; None; Oral	HbA1c change	%	8.3	0.7	Not applicable	Not applicable	Not applicable	106
Kumar 2014	Saxagliptin; 5 mg daily; Oral	HbA1c change	%	8.3	0.8	Not applicable	Not applicable	Not applicable	102
Lambadiari 2018	Liraglutide; 1.8 mg daily; Subcutaneous	BMI change	kg/m2	32.9	5	Not applicable	Not applicable	Not applicable	30
Lambadiari 2018	Liraglutide; 1.8 mg daily; Subcutaneous	HbA1c change	%	8.6	2	Not applicable	Not applicable	Not applicable	30
Lambadiari 2018	Liraglutide; 1.8 mg daily; Subcutaneous	Weight change	kg	98	16	Not applicable	Not applicable	Not applicable	30
Lambadiari 2018	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	27.7	2	Not applicable	Not applicable	Not applicable	30

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Lambadiari 2018	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	8.4	1.2	Not applicable	Not applicable	Not applicable	30
Lambadiari 2018	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	78	12	Not applicable	Not applicable	Not applicable	30
Lee 2013A	Pioglitazone; 15 mg daily; Oral	BMI change	kg/m2	24.8	4.1	Not applicable	Not applicable	Not applicable	25
Lee 2013A	Placebo; None; Oral	BMI change	kg/m2	24.1	3	Not applicable	Not applicable	Not applicable	25
Lewin 2015	Empagliflozin + Linagliptin; 10 mg + 5 mg daily; Oral	BMI change	kg/m2	31.5	5.6	Not applicable	Not applicable	Not applicable	135
Lewin 2015	Empagliflozin + Linagliptin; 10 mg + 5 mg daily; Oral	HbA1c change	%	8.04	0.96	Not applicable	Not applicable	Not applicable	135
Lewin 2015	Empagliflozin + Linagliptin; 10 mg + 5	Weight change	kg	87.3	18.4	Not applicable	Not applicable	Not applicable	135

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	mg daily; Oral								
Lewin 2015	Empagliflozin + Linagliptin; 10-25 + 5 mg daily combined; Oral	BMI change	kg/m2	31.65	5.44	Not applicable	Not applicable	Not applicable	269
Lewin 2015	Empagliflozin + Linagliptin; 10-25 + 5 mg daily combined; Oral	HbA1c change	%	8.02	0.95	Not applicable	Not applicable	Not applicable	269
Lewin 2015	Empagliflozin + Linagliptin; 10-25 + 5 mg daily combined; Oral	Weight change	kg	87.6	18.47	Not applicable	Not applicable	Not applicable	269
Lewin 2015	Empagliflozin + Linagliptin; 25 mg + 5 mg daily; Oral	BMI change	kg/m2	31.8	5.3	Not applicable	Not applicable	Not applicable	134
Lewin 2015	Empagliflozin + Linagliptin; 25 mg + 5 mg daily; Oral	HbA1c change	%	7.99	0.95	Not applicable	Not applicable	Not applicable	134

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Lewin 2015	Empagliflozin + Linagliptin; 25 mg + 5 mg daily; Oral	Weight change	kg	87.9	18.6	Not applicable	Not applicable	Not applicable	134
Lewin 2015	Empagliflozin ; 10 mg daily; Oral	BMI change	kg/m2	31.5	5.7	Not applicable	Not applicable	Not applicable	132
Lewin 2015	Empagliflozin ; 10 mg daily; Oral	HbA1c change	%	8.05	1.03	Not applicable	Not applicable	Not applicable	132
Lewin 2015	Empagliflozin ; 10 mg daily; Oral	Weight change	kg	87.8	24	Not applicable	Not applicable	Not applicable	132
Lewin 2015	Empagliflozin ; 10-25 mg daily combined; Oral	BMI change	kg/m2	31.3	5.7	Not applicable	Not applicable	Not applicable	265
Lewin 2015	Empagliflozin ; 10-25 mg daily combined; Oral	HbA1c change	%	8.02	1	Not applicable	Not applicable	Not applicable	265
Lewin 2015	Empagliflozin ; 10-25 mg daily combined; Oral	Weight change	kg	87.2	22	Not applicable	Not applicable	Not applicable	265

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Lewin 2015	Empagliflozin ; 25 mg daily; Oral	BMI change	kg/m2	31.2	5.7	Not applicable	Not applicable	Not applicable	133
Lewin 2015	Empagliflozin ; 25 mg daily; Oral	HbA1c change	%	7.99	0.97	Not applicable	Not applicable	Not applicable	133
Lewin 2015	Empagliflozin ; 25 mg daily; Oral	Weight change	kg	86.7	19.7	Not applicable	Not applicable	Not applicable	133
Lewin 2015	Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	31.9	5.9	Not applicable	Not applicable	Not applicable	133
Lewin 2015	Linagliptin; 5 mg daily; Oral	HbA1c change	%	8.05	0.89	Not applicable	Not applicable	Not applicable	133
Lewin 2015	Linagliptin; 5 mg daily; Oral	Weight change	kg	89.5	20.1	Not applicable	Not applicable	Not applicable	133
Li 2019A	Glimepiride; 2 mg daily; Oral	BMI change	kg/m2	27.2	4.06	Not applicable	Not applicable	Not applicable	31
Li 2019A	Glimepiride; 2 mg daily; Oral	HbA1c change	%	7.79	0.52	Not applicable	Not applicable	Not applicable	31
Li 2019A	Saxagliptin; 5 mg daily; Oral	BMI change	kg/m2	26.46	3.23	Not applicable	Not applicable	Not applicable	33

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Li 2019A	Saxagliptin; 5 mg daily; Oral	HbA1c change	%	7.57	1.24	Not applicable	Not applicable	Not applicable	33
Liu 2020	Exenatide; 10-20 mcg daily; Subcutaneous	BMI change	kg/m2	28.49	3.02	Not applicable	Not applicable	Not applicable	38
Liu 2020	Exenatide; 10-20 mcg daily; Subcutaneous	HbA1c change	%	8.32	0.94	Not applicable	Not applicable	Not applicable	38
Liu 2020	Exenatide; 10-20 mcg daily; Subcutaneous	Weight change	kg	79.28	9.64	Not applicable	Not applicable	Not applicable	38
Liu 2020	Insulin glargine; 0.1-0.3 units/kg daily; Subcutaneous	BMI change	kg/m2	27.84	3.1	Not applicable	Not applicable	Not applicable	38
Liu 2020	Insulin glargine; 0.1-0.3 units/kg daily;	HbA1c change	%	8.58	0.91	Not applicable	Not applicable	Not applicable	38

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	Subcutaneous								
Liu 2020	Insulin glargine; 0.1-0.3 units/kg daily; Subcutaneous	Weight change	kg	77.63	13.7	Not applicable	Not applicable	Not applicable	38
Mari 2008	Placebo; None; Oral	BMI change	kg/m2	30	4.9	Not applicable	Not applicable	Not applicable	150
Mari 2008	Placebo; None; Oral	HbA1c change	%	6.8	0.4	Not applicable	Not applicable	Not applicable	150
Mari 2008	Placebo; None; Oral	Weight change	kg	85	14.7	1.4	Not applicable	Not applicable	150
Mari 2008	Vildagliptin; 50 mg daily; Oral	BMI change	kg/m2	30.4	4.9	Not applicable	Not applicable	Not applicable	156
Mari 2008	Vildagliptin; 50 mg daily; Oral	HbA1c change	%	6.7	0.4	Not applicable	Not applicable	Not applicable	156
Mari 2008	Vildagliptin; 50 mg daily; Oral	Weight change	kg	86	14.99	1.2	Not applicable	Not applicable	156
Mita 2019	Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	25.7	4.5	Not applicable	Not applicable	Not applicable	21

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Mita 2019	Linagliptin; 5 mg daily; Oral	HbA1c change	%	7.1	0.7	Not applicable	Not applicable	Not applicable	21
Mita 2019	Metformin type unspecified; 2250 mg daily; Oral	BMI change	kg/m2	26.3	4.9	Not applicable	Not applicable	Not applicable	22
Mita 2019	Metformin type unspecified; 2250 mg daily; Oral	HbA1c change	%	7.5	1.5	Not applicable	Not applicable	Not applicable	21
Miyagawa 2015	Dulaglutide; 0.75 mg weekly; Subcutaneous	BMI change	kg/m2	25.6	3.6	Not applicable	Not applicable	Not applicable	281
Miyagawa 2015	Dulaglutide; 0.75 mg weekly; Subcutaneous	HbA1c change	%	8.15	0.77	Not applicable	Not applicable	Not applicable	281
Miyagawa 2015	Dulaglutide; 0.75 mg weekly; Subcutaneous	Weight change	kg	71.3	12.5	Not applicable	Not applicable	Not applicable	281

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Miyagawa 2015	Liraglutide; 0.9 mg daily; Subcutaneous	BMI change	kg/m2	25.5	3.5	Not applicable	Not applicable	Not applicable	141
Miyagawa 2015	Liraglutide; 0.9 mg daily; Subcutaneous	HbA1c change	%	8.08	0.89	Not applicable	Not applicable	Not applicable	141
Miyagawa 2015	Liraglutide; 0.9 mg daily; Subcutaneous	Weight change	kg	70.2	12.5	Not applicable	Not applicable	Not applicable	141
Miyagawa 2015	Placebo; None; Subcutaneous	BMI change	kg/m2	25.2	3.2	Not applicable	Not applicable	Not applicable	79
Miyagawa 2015	Placebo; None; Subcutaneous	HbA1c change	%	8.2	0.83	Not applicable	Not applicable	Not applicable	79
Miyagawa 2015	Placebo; None; Subcutaneous	Weight change	kg	69.3	11.6	Not applicable	Not applicable	Not applicable	79
Miyazaki 2002	Pioglitazone; 15 mg daily; Oral	BMI change	kg/m2	30.8	1.3	Not applicable	Not applicable	Not applicable	12

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Miyazaki 2002	Pioglitazone; 15 mg daily; Oral	HbA1c change	%	8	0.3	Not applicable	Not applicable	Not applicable	12
Miyazaki 2002	Pioglitazone; 15 mg daily; Oral	Weight change	kg	93	5	Not applicable	Not applicable	Not applicable	12
Miyazaki 2002	Pioglitazone; 30 mg daily; Oral	BMI change	kg/m2	32.2	1.6	Not applicable	Not applicable	Not applicable	11
Miyazaki 2002	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	8.5	0.5	Not applicable	Not applicable	Not applicable	11
Miyazaki 2002	Pioglitazone; 30 mg daily; Oral	Weight change	kg	97	4	Not applicable	Not applicable	Not applicable	11
Miyazaki 2002	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	30.4	1	Not applicable	Not applicable	Not applicable	11
Miyazaki 2002	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	9.1	0.3	Not applicable	Not applicable	Not applicable	11
Miyazaki 2002	Pioglitazone; 45 mg daily; Oral	Weight change	kg	86	3	Not applicable	Not applicable	Not applicable	11
Miyazaki 2002	Pioglitazone; 7.5 mg daily; Oral	BMI change	kg/m2	31.3	1.2	Not applicable	Not applicable	Not applicable	13

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Miyazaki 2002	Pioglitazone; 7.5 mg daily; Oral	HbA1c change	%	8.9	0.4	Not applicable	Not applicable	Not applicable	13
Miyazaki 2002	Pioglitazone; 7.5 mg daily; Oral	Weight change	kg	93	5	Not applicable	Not applicable	Not applicable	13
Miyazaki 2002	Pioglitazone; 7.5-45 mg daily combined; Oral	BMI change	kg/m2	31.17	1.45	Not applicable	Not applicable	Not applicable	47
Miyazaki 2002	Pioglitazone; 7.5-45 mg daily combined; Oral	HbA1c change	%	8.62	0.57	Not applicable	Not applicable	Not applicable	47
Miyazaki 2002	Pioglitazone; 7.5-45 mg daily combined; Oral	Weight change	kg	92	6	Not applicable	Not applicable	Not applicable	47
Miyazaki 2002	Placebo; None; Oral	BMI change	kg/m2	32.8	1.6	Not applicable	Not applicable	Not applicable	11
Miyazaki 2002	Placebo; None; Oral	HbA1c change	%	8.6	0.5	Not applicable	Not applicable	Not applicable	11
Miyazaki 2002	Placebo; None; Oral	Weight change	kg	90	4	Not applicable	Not applicable	Not applicable	11

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Moretto 2008	Exenatide; 10 mcg daily; Subcutaneous	BMI change	kg/m2	31	5	Not applicable	Not applicable	Not applicable	78
Moretto 2008	Exenatide; 10 mcg daily; Subcutaneous	HbA1c change	%	7.8	1	Not applicable	Not applicable	Not applicable	78
Moretto 2008	Exenatide; 10 mcg daily; Subcutaneous	Weight change	kg	86	16	Not applicable	Not applicable	Not applicable	78
Moretto 2008	Exenatide; 5 mcg daily; Subcutaneous	BMI change	kg/m2	32	5	Not applicable	Not applicable	Not applicable	77
Moretto 2008	Exenatide; 5 mcg daily; Subcutaneous	HbA1c change	%	7.9	1	Not applicable	Not applicable	Not applicable	77
Moretto 2008	Exenatide; 5 mcg daily; Subcutaneous	Weight change	kg	85	15	Not applicable	Not applicable	Not applicable	77
Moretto 2008	Exenatide; 5-10 mcg daily combined; Subcutaneous	BMI change	kg/m2	31.5	5	Not applicable	Not applicable	Not applicable	155

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Moretto 2008	Exenatide; 5-10 mcg daily combined; Subcutaneous	HbA1c change	%	7.85	1	Not applicable	Not applicable	Not applicable	155
Moretto 2008	Exenatide; 5-10 mcg daily combined; Subcutaneous	Weight change	kg	85.5	15.47	Not applicable	Not applicable	Not applicable	155
Moretto 2008	Placebo; None; Subcutaneous	BMI change	kg/m2	32	5	Not applicable	Not applicable	Not applicable	78
Moretto 2008	Placebo; None; Subcutaneous	HbA1c change	%	7.8	0.9	Not applicable	Not applicable	Not applicable	78
Moretto 2008	Placebo; None; Subcutaneous	Weight change	kg	86	16	Not applicable	Not applicable	Not applicable	78
Mu 2017	Linagliptin + Metformin; 2.5 mg + 1000 mg daily; Oral	BMI change	kg/m2	26	3.6	Not applicable	Not applicable	Not applicable	147
Mu 2017	Linagliptin + Metformin;	HbA1c change	%	8.7	0.9	Not applicable	Not applicable	Not applicable	147

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	2.5 mg + 1000 mg daily; Oral								
Mu 2017	Linagliptin + Metformin; 2.5 mg + 1000 mg daily; Oral	Weight change	kg	70.8	12	Not applicable	Not applicable	Not applicable	147
Mu 2017	Linagliptin + Metformin; 2.5 mg + 2000 mg daily; Oral	BMI change	kg/m2	26	3.7	Not applicable	Not applicable	Not applicable	147
Mu 2017	Linagliptin + Metformin; 2.5 mg + 2000 mg daily; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	147
Mu 2017	Linagliptin + Metformin; 2.5 mg + 2000 mg daily; Oral	Weight change	kg	70.5	12	Not applicable	Not applicable	Not applicable	147
Mu 2017	Linagliptin + Metformin; 5 mg + 1000-2000 mg daily combined; Oral	BMI change	kg/m2	26	3.65	Not applicable	Not applicable	Not applicable	294

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Mu 2017	Linagliptin + Metformin; 5 mg + 1000-2000 mg daily combined; Oral	HbA1c change	%	8.7	0.95	Not applicable	Not applicable	Not applicable	294
Mu 2017	Linagliptin + Metformin; 5 mg + 1000-2000 mg daily combined; Oral	Weight change	kg	70.65	12	Not applicable	Not applicable	Not applicable	294
Mu 2017	Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	26.2	3.9	Not applicable	Not applicable	Not applicable	147
Mu 2017	Linagliptin; 5 mg daily; Oral	HbA1c change	%	8.7	0.9	Not applicable	Not applicable	Not applicable	147
Mu 2017	Linagliptin; 5 mg daily; Oral	Weight change	kg	70.2	13.5	Not applicable	Not applicable	Not applicable	147
Mu 2017	Metformin type unspecified; 1000 mg daily; Oral	BMI change	kg/m2	25.8	3.3	Not applicable	Not applicable	Not applicable	145

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Mu 2017	Metformin type unspecified; 1000 mg daily; Oral	HbA1c change	%	8.7	1.1	Not applicable	Not applicable	Not applicable	145
Mu 2017	Metformin type unspecified; 1000 mg daily; Oral	Weight change	kg	69.1	10.7	Not applicable	Not applicable	Not applicable	145
Mu 2017	Metformin type unspecified; 1000-2000 mg daily combined; Oral	BMI change	kg/m2	25.95	3.3	Not applicable	Not applicable	Not applicable	289
Mu 2017	Metformin type unspecified; 1000-2000 mg daily combined; Oral	HbA1c change	%	8.65	1.05	Not applicable	Not applicable	Not applicable	289
Mu 2017	Metformin type unspecified; 1000-2000 mg daily	Weight change	kg	70.05	11.51	Not applicable	Not applicable	Not applicable	289

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	combined; Oral								
Mu 2017	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	26.1	3.3	Not applicable	Not applicable	Not applicable	144
Mu 2017	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	8.6	1	Not applicable	Not applicable	Not applicable	144
Mu 2017	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	71	12.2	Not applicable	Not applicable	Not applicable	144
Nauck 2016	Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	32.7	5.3	Not applicable	Not applicable	Not applicable	135
Nauck 2016	Linagliptin; 5 mg daily; Oral	HbA1c change	%	8	0.9	Not applicable	Not applicable	Not applicable	130
Nauck 2016	Linagliptin; 5 mg daily; Oral	Weight change	kg	94.7	19.3	Not applicable	Not applicable	Not applicable	135
Nauck 2016	Pioglitazone + Linagliptin; 15 mg + 5	BMI change	kg/m2	32.4	5.5	Not applicable	Not applicable	Not applicable	126

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	mg daily; Oral								
Nauck 2016	Pioglitazone + Linagliptin; 15 mg + 5 mg daily; Oral	HbA1c change	%	8.1	0.9	Not applicable	Not applicable	Not applicable	120
Nauck 2016	Pioglitazone + Linagliptin; 15 mg + 5 mg daily; Oral	Weight change	kg	93.6	19	Not applicable	Not applicable	Not applicable	126
Nauck 2016	Pioglitazone + Linagliptin; 15-45 mg + 5 mg daily combined; Oral	BMI change	kg/m2	32.47	5.52	Not applicable	Not applicable	Not applicable	392
Nauck 2016	Pioglitazone + Linagliptin; 15-45 mg + 5 mg daily combined; Oral	HbA1c change	%	8.1	0.94	Not applicable	Not applicable	Not applicable	371
Nauck 2016	Pioglitazone + Linagliptin; 15-45 mg + 5 mg daily combined; Oral	Weight change	kg	92.38	18.91	Not applicable	Not applicable	Not applicable	392

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Nauck 2016	Pioglitazone + Linagliptin; 30 mg + 5 mg daily; Oral	BMI change	kg/m2	32.6	5.7	Not applicable	Not applicable	Not applicable	133
Nauck 2016	Pioglitazone + Linagliptin; 30 mg + 5 mg daily; Oral	HbA1c change	%	8.2	1.1	Not applicable	Not applicable	Not applicable	125
Nauck 2016	Pioglitazone + Linagliptin; 30 mg + 5 mg daily; Oral	Weight change	kg	91.8	19.3	Not applicable	Not applicable	Not applicable	133
Nauck 2016	Pioglitazone + Linagliptin; 45 mg + 5 mg daily; Oral	BMI change	kg/m2	32.4	5.4	Not applicable	Not applicable	Not applicable	133
Nauck 2016	Pioglitazone + Linagliptin; 45 mg + 5 mg daily; Oral	HbA1c change	%	8	0.8	Not applicable	Not applicable	Not applicable	126
Nauck 2016	Pioglitazone + Linagliptin; 45 mg + 5	Weight change	kg	91.8	18.5	Not applicable	Not applicable	Not applicable	133

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	mg daily; Oral								
Nauck 2016	Pioglitazone; 15 mg daily; Oral	BMI change	kg/m2	32.3	5.6	Not applicable	Not applicable	Not applicable	131
Nauck 2016	Pioglitazone; 15 mg daily; Oral	HbA1c change	%	8.3	0.9	Not applicable	Not applicable	Not applicable	124
Nauck 2016	Pioglitazone; 15 mg daily; Oral	Weight change	kg	91.5	20.7	Not applicable	Not applicable	Not applicable	131
Nauck 2016	Pioglitazone; 15-45 mg daily combined; Oral	BMI change	kg/m2	32.84	5.5	Not applicable	Not applicable	Not applicable	409
Nauck 2016	Pioglitazone; 15-45 mg daily combined; Oral	HbA1c change	%	8.13	0.91	Not applicable	Not applicable	Not applicable	392
Nauck 2016	Pioglitazone; 15-45 mg daily combined; Oral	Weight change	kg	93.32	19.98	Not applicable	Not applicable	Not applicable	409
Nauck 2016	Pioglitazone; 30 mg daily; Oral	BMI change	kg/m2	32.3	5.3	Not applicable	Not applicable	Not applicable	140

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Nauck 2016	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	8	0.9	Not applicable	Not applicable	Not applicable	134
Nauck 2016	Pioglitazone; 30 mg daily; Oral	Weight change	kg	91.5	19.9	Not applicable	Not applicable	Not applicable	140
Nauck 2016	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	33.9	5.5	Not applicable	Not applicable	Not applicable	138
Nauck 2016	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	8.1	0.9	Not applicable	Not applicable	Not applicable	134
Nauck 2016	Pioglitazone; 45 mg daily; Oral	Weight change	kg	96.9	19	Not applicable	Not applicable	Not applicable	138
Pan 2012A	Placebo; None; Oral	BMI change	kg/m2	25.9	3.7	Not applicable	Not applicable	Not applicable	284
Pan 2012A	Placebo; None; Oral	HbA1c change	%	8.2	0.8	Not applicable	Not applicable	Not applicable	284
Pan 2012A	Placebo; None; Oral	Weight change	kg	69.2	12.4	Not applicable	Not applicable	Not applicable	284
Pan 2012A	Saxagliptin; 5 mg daily; Oral	BMI change	kg/m2	25.9	3.4	Not applicable	Not applicable	Not applicable	284
Pan 2012A	Saxagliptin; 5 mg daily; Oral	HbA1c change	%	8.1	0.8	Not applicable	Not applicable	Not applicable	284

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Pan 2012A	Saxagliptin; 5 mg daily; Oral	Weight change	kg	69.2	11.4	Not applicable	Not applicable	Not applicable	284
Pavo 2003	Metformin type unspecified; 850-2550 mg daily; Oral	HbA1c change	%	8.6	Not applicable	Not applicable	Not applicable	Not applicable	100
Pavo 2003	Metformin type unspecified; 850-2550 mg daily; Oral	Weight change	kg	88.8	Not applicable	Not applicable	Not applicable	Not applicable	100
Pavo 2003	Pioglitazone; 30-45 mg daily; Oral	HbA1c change	%	8.6	Not applicable	Not applicable	Not applicable	Not applicable	105
Pavo 2003	Pioglitazone; 30-45 mg daily; Oral	Weight change	kg	86.1	Not applicable	Not applicable	Not applicable	Not applicable	105
Perez 2009	Pioglitazone + Metformin; 30 mg + 1500 mg daily; Oral	BMI change	kg/m2	30.8	5.7	Not applicable	Not applicable	Not applicable	210
Perez 2009	Pioglitazone + Metformin; 30 mg + 1500 mg daily; Oral	HbA1c change	%	8.65	1.01	0.07	Not applicable	Not applicable	210

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Perez 2009	Pioglitazone; 30 mg daily; Oral	BMI change	kg/m2	31.2	5.5	Not applicable	Not applicable	Not applicable	189
Perez 2009	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	8.69	0.96	0.07	Not applicable	Not applicable	189
Perez 2009	Standard care; None; Oral	BMI change	kg/m2	30.8	5.7	Not applicable	Not applicable	Not applicable	201
Perez 2009	Standard care; None; Oral	HbA1c change	%	8.89	0.99	0.07	Not applicable	Not applicable	201
Pfützner 2011A	Metformin type unspecified; 500-2000 mg daily; Oral	BMI change	kg/m2	30.2	4.9	Not applicable	Not applicable	Not applicable	328
Pfützner 2011A	Metformin type unspecified; 500-2000 mg daily; Oral	HbA1c change	%	9.4	1.3	Not applicable	Not applicable	Not applicable	328
Pfützner 2011A	Saxagliptin + Metformin; 10 mg + 500-2000 mg daily; Oral	BMI change	kg/m2	30.2	4.7	Not applicable	Not applicable	Not applicable	643
Pfützner 2011A	Saxagliptin + Metformin; 5-	HbA1c change	%	9.5	1.2	Not applicable	Not applicable	Not applicable	643

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	10 mg + 500-2000 mg daily combined; Oral								
Pfützner 2011A	Saxagliptin; 10 mg daily; Oral	BMI change	kg/m2	30.2	4.9	Not applicable	Not applicable	Not applicable	335
Pfützner 2011A	Saxagliptin; 10 mg daily; Oral	HbA1c change	%	9.6	1.3	Not applicable	Not applicable	Not applicable	335
Pistrosch 2013	Insulin glargine; Titrated; Subcutaneous	BMI change	kg/m2	29.2	4.6	Not applicable	Not applicable	Not applicable	39
Pistrosch 2013	Insulin glargine; Titrated; Subcutaneous	HbA1c change	%	6.36	0.4	Not applicable	Not applicable	Not applicable	39
Pistrosch 2013	Insulin glargine; Titrated; Subcutaneous	Weight change	kg	87.6	15.1	Not applicable	Not applicable	Not applicable	39
Pistrosch 2013	Metformin type unspecified;	BMI change	kg/m2	29.9	5.3	Not applicable	Not applicable	Not applicable	36

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	2000 mg daily; Oral								
Pistrosch 2013	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	6.9	0.4	Not applicable	Not applicable	Not applicable	36
Pistrosch 2013	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	87.6	17.9	Not applicable	Not applicable	Not applicable	36
Pi-Sunyer 2007	Placebo; None; Oral	BMI change	kg/m2	32.7	6.4	Not applicable	Not applicable	Not applicable	92
Pi-Sunyer 2007	Placebo; None; Oral	HbA1c change	%	8.5	0.8	Not applicable	Not applicable	Not applicable	92
Pi-Sunyer 2007	Placebo; None; Oral	Weight change	kg	93	23.2	Not applicable	Not applicable	Not applicable	92
Pi-Sunyer 2007	Vildagliptin; 100 mg daily B; Oral	BMI change	kg/m2	32.2	6	Not applicable	Not applicable	Not applicable	83
Pi-Sunyer 2007	Vildagliptin; 100 mg daily B; Oral	HbA1c change	%	8.4	0.9	Not applicable	Not applicable	Not applicable	83
Pi-Sunyer 2007	Vildagliptin; 100 mg daily B; Oral	Weight change	kg	89.9	18.5	Not applicable	Not applicable	Not applicable	83

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Pi-Sunyer 2007	Vildagliptin; 100 mg daily; Oral	BMI change	kg/m2	31.9	5	Not applicable	Not applicable	Not applicable	91
Pi-Sunyer 2007	Vildagliptin; 100 mg daily; Oral	HbA1c change	%	8.3	0.8	Not applicable	Not applicable	Not applicable	91
Pi-Sunyer 2007	Vildagliptin; 100 mg daily; Oral	Weight change	kg	90.8	19.9	Not applicable	Not applicable	Not applicable	91
Pi-Sunyer 2007	Vildagliptin; 50 mg daily; Oral	BMI change	kg/m2	31.9	5.4	Not applicable	Not applicable	Not applicable	88
Pi-Sunyer 2007	Vildagliptin; 50 mg daily; Oral	HbA1c change	%	8.4	0.9	Not applicable	Not applicable	Not applicable	88
Pi-Sunyer 2007	Vildagliptin; 50 mg daily; Oral	Weight change	kg	90.5	22.3	Not applicable	Not applicable	Not applicable	88
Pi-Sunyer 2007	Vildagliptin; 50-100 mg daily combined; Oral	BMI change	kg/m2	32	5.45	Not applicable	Not applicable	Not applicable	262
Pi-Sunyer 2007	Vildagliptin; 50-100 mg daily combined; Oral	HbA1c change	%	8.37	0.86	Not applicable	Not applicable	Not applicable	262

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Pi-Sunyer 2007	Vildagliptin; 50-100 mg daily combined; Oral	Weight change	kg	90.41	20.25	Not applicable	Not applicable	Not applicable	262
Pratley 2014	Alogliptin + Metformin; 25 mg + 2000 mg daily; Oral	BMI change	kg/m2	31.2	5.3	Not applicable	Not applicable	Not applicable	109
Pratley 2014	Alogliptin; 25 mg daily B; Oral	BMI change	kg/m2	31	5.4	Not applicable	Not applicable	Not applicable	225
Pratley 2014	Alogliptin; 25 mg daily; Oral	BMI change	kg/m2	30.6	5.2	Not applicable	Not applicable	Not applicable	225
Pratley 2014	Alogliptin; 25 mg once daily or 12.5 mg twice daily combined; Oral	BMI change	kg/m2	30.4	4.9	Not applicable	Not applicable	Not applicable	225
Roden 2005 1.1	Metformin type unspecified; 850-2550 mg daily; Oral	BMI change	kg/m2	31.4	5.2	Not applicable	Not applicable	Not applicable	597

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Roden 2005 1.1	Metformin type unspecified; 850-2550 mg daily; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	597
Roden 2005 1.1	Metformin type unspecified; 850-2550 mg daily; Oral	Weight change	kg	89.7	16.6	Not applicable	Not applicable	Not applicable	597
Roden 2005 1.1	Pioglitazone; 30-45 mg daily; Oral	BMI change	kg/m2	31.2	4.9	Not applicable	Not applicable	Not applicable	597
Roden 2005 1.1	Pioglitazone; 30-45 mg daily; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	597
Roden 2005 1.1	Pioglitazone; 30-45 mg daily; Oral	Weight change	kg	88.2	15.5	Not applicable	Not applicable	Not applicable	597
Roden 2015	Empagliflozin ; 10 mg daily; Oral	BMI change	kg/m2	28.3	5.5	Not applicable	Not applicable	Not applicable	224
Roden 2015	Empagliflozin ; 10 mg daily; Oral	HbA1c change	%	7.87	0.88	Not applicable	Not applicable	Not applicable	224
Roden 2015	Empagliflozin ; 10 mg daily; Oral	Weight change	kg	78.4	18.7	Not applicable	Not applicable	Not applicable	224

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Roden 2015	Empagliflozin ; 10-25 mg daily combined; Oral	BMI change	kg/m2	28.25	5.49	Not applicable	Not applicable	Not applicable	448
Roden 2015	Empagliflozin ; 10-25 mg daily combined; Oral	HbA1c change	%	7.87	0.86	Not applicable	Not applicable	Not applicable	448
Roden 2015	Empagliflozin ; 10-25 mg daily combined; Oral	Weight change	kg	78.1	18.34	Not applicable	Not applicable	Not applicable	448
Roden 2015	Empagliflozin ; 25 mg daily; Oral	BMI change	kg/m2	28.2	5.5	Not applicable	Not applicable	Not applicable	224
Roden 2015	Empagliflozin ; 25 mg daily; Oral	HbA1c change	%	7.86	0.85	Not applicable	Not applicable	Not applicable	224
Roden 2015	Empagliflozin ; 25 mg daily; Oral	Weight change	kg	77.8	18	Not applicable	Not applicable	Not applicable	224
Roden 2015	Placebo; None; Oral	BMI change	kg/m2	28.7	6.2	Not applicable	Not applicable	Not applicable	228
Roden 2015	Placebo; None; Oral	HbA1c change	%	7.91	0.78	Not applicable	Not applicable	Not applicable	228

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Roden 2015	Placebo; None; Oral	Weight change	kg	78.2	19.9	Not applicable	Not applicable	Not applicable	228
Roden 2015	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	28.2	5.2	Not applicable	Not applicable	Not applicable	223
Roden 2015	Sitagliptin; 100 mg daily; Oral	HbA1c change	%	7.85	0.79	Not applicable	Not applicable	Not applicable	223
Roden 2015	Sitagliptin; 100 mg daily; Oral	Weight change	kg	79.3	20.4	Not applicable	Not applicable	Not applicable	223
Rosenstock 2007A	Pioglitazone + Vildagliptin; 15 mg + 50 mg daily; Oral	BMI change	kg/m2	29	5.4	Not applicable	Not applicable	Not applicable	144
Rosenstock 2007A	Pioglitazone + Vildagliptin; 15 mg + 50 mg daily; Oral	HbA1c change	%	8.8	0.9	Not applicable	Not applicable	Not applicable	144
Rosenstock 2007A	Pioglitazone + Vildagliptin; 15-30 mg + 50-100 mg daily combined; Oral	BMI change	kg/m2	29.3	5.6	Not applicable	Not applicable	Not applicable	292

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Rosenstock 2007A	Pioglitazone + Vildagliptin; 15-30 mg + 50-100 mg daily combined; Oral	HbA1c change	%	8.8	1	Not applicable	Not applicable	Not applicable	292
Rosenstock 2007A	Pioglitazone + Vildagliptin; 30 mg + 100 mg daily; Oral	BMI change	kg/m2	29.6	5.8	Not applicable	Not applicable	Not applicable	148
Rosenstock 2007A	Pioglitazone + Vildagliptin; 30 mg + 100 mg daily; Oral	HbA1c change	%	8.8	1.1	Not applicable	Not applicable	Not applicable	148
Rosenstock 2007A	Pioglitazone; 30 mg daily; Oral	BMI change	kg/m2	28.9	5.5	Not applicable	Not applicable	Not applicable	161
Rosenstock 2007A	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	161
Rosenstock 2007A	Vildagliptin; 100 mg daily; Oral	BMI change	kg/m2	29.4	5.8	Not applicable	Not applicable	Not applicable	154
Rosenstock 2007A	Vildagliptin; 100 mg daily; Oral	HbA1c change	%	8.6	1	Not applicable	Not applicable	Not applicable	154

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Rosenstock 2009A	Placebo; None; Oral	BMI change	kg/m2	30.93	4.26	Not applicable	Not applicable	Not applicable	95
Rosenstock 2009A	Placebo; None; Oral	HbA1c change	%	7.9	0.9	Not applicable	Not applicable	Not applicable	95
Rosenstock 2009A	Placebo; None; Oral	Weight change	kg	86.56	16.9	Not applicable	Not applicable	Not applicable	95
Rosenstock 2009A	Saxagliptin; 10 mg daily; Oral	BMI change	kg/m2	31.71	4.71	Not applicable	Not applicable	Not applicable	98
Rosenstock 2009A	Saxagliptin; 10 mg daily; Oral	HbA1c change	%	7.8	0.9	Not applicable	Not applicable	Not applicable	98
Rosenstock 2009A	Saxagliptin; 10 mg daily; Oral	Weight change	kg	89.3	17.67	Not applicable	Not applicable	Not applicable	98
Rosenstock 2009A	Saxagliptin; 2.5 mg daily; Oral	BMI change	kg/m2	31.9	4.82	Not applicable	Not applicable	Not applicable	102
Rosenstock 2009A	Saxagliptin; 2.5 mg daily; Oral	HbA1c change	%	7.9	0.9	Not applicable	Not applicable	Not applicable	102
Rosenstock 2009A	Saxagliptin; 2.5 mg daily; Oral	Weight change	kg	92.1	18.39	Not applicable	Not applicable	Not applicable	102
Rosenstock 2009A	Saxagliptin; 2.5-10 mg daily	BMI change	kg/m2	31.96	4.68	Not applicable	Not applicable	Not applicable	306

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	combined; Oral								
Rosenstock 2009A	Saxagliptin; 2.5-10 mg daily combined; Oral	HbA1c change	%	7.9	0.98	Not applicable	Not applicable	Not applicable	306
Rosenstock 2009A	Saxagliptin; 2.5-10 mg daily combined; Oral	Weight change	kg	90.78	18.11	Not applicable	Not applicable	Not applicable	306
Rosenstock 2009A	Saxagliptin; 5 mg daily; Oral	BMI change	kg/m2	32.24	4.5	Not applicable	Not applicable	Not applicable	106
Rosenstock 2009A	Saxagliptin; 5 mg daily; Oral	HbA1c change	%	8	1.1	Not applicable	Not applicable	Not applicable	106
Rosenstock 2009A	Saxagliptin; 5 mg daily; Oral	Weight change	kg	90.87	18.15	Not applicable	Not applicable	Not applicable	106
Rosenstock 2010	Alogliptin; 25 mg daily; Oral	HbA1c change	%	8.8	0.99	Not applicable	Not applicable	Not applicable	164
Rosenstock 2010	Pioglitazone + Alogliptin 12.5 mg; 30 mg + 12.5	HbA1c change	%	8.85	1.04	Not applicable	Not applicable	Not applicable	163

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	mg daily; Oral								
Rosenstock 2010	Pioglitazone + Alogliptin 25 mg; 30 mg + 25 mg daily; Oral	HbA1c change	%	8.8	0.97	Not applicable	Not applicable	Not applicable	164
Rosenstock 2010	Pioglitazone + Alogliptin; 30 mg + 12.5/25mg combined; Oral	HbA1c change	%	8.83	1	Not applicable	Not applicable	Not applicable	327
Rosenstock 2010	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	8.76	1.01	Not applicable	Not applicable	Not applicable	163
Rosenstock 2016	Canagliflozin + Metformin; 100 mg + 500-2000 mg daily; Oral	BMI change	kg/m2	31.9	5.3	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Canagliflozin + Metformin; 100 mg + 500-2000 mg daily; Oral	HbA1c change	%	8.8	1.1	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Canagliflozin + Metformin; 100 mg +	Weight change	kg	88.3	17.6	Not applicable	Not applicable	Not applicable	237

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	500-2000 mg daily; Oral								
Rosenstock 2016	Canagliflozin + Metformin; 100-300 mg + 500-2000 mg daily; Oral	BMI change	kg/m2	32.4	6	Not applicable	Not applicable	Not applicable	474
Rosenstock 2016	Canagliflozin + Metformin; 100-300 mg + 500-2000 mg daily; Oral	HbA1c change	%	8.9	1.2	Not applicable	Not applicable	Not applicable	474
Rosenstock 2016	Canagliflozin + Metformin; 100-300 mg + 500-2000 mg daily; Oral	Weight change	kg	89.9	19.7	Not applicable	Not applicable	Not applicable	474
Rosenstock 2016	Canagliflozin + Metformin; 300 mg + 500-2000 mg daily; Oral	BMI change	kg/m2	32.8	6.5	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Canagliflozin + Metformin; 300 mg + 500-2000 mg daily; Oral	HbA1c change	%	8.9	1.2	Not applicable	Not applicable	Not applicable	237

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Rosenstock 2016	Canagliflozin + Metformin; 300 mg + 500-2000 mg daily; Oral	Weight change	kg	91.4	21.4	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Canagliflozin; 100 mg daily; Oral	BMI change	kg/m2	32.4	5.4	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Canagliflozin; 100 mg daily; Oral	HbA1c change	%	8.8	1.2	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Canagliflozin; 100 mg daily; Oral	Weight change	kg	92.1	20.1	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Canagliflozin; 100-300 mg daily combined; Oral	BMI change	kg/m2	32.5	5.6	Not applicable	Not applicable	Not applicable	475
Rosenstock 2016	Canagliflozin; 100-300 mg daily combined; Oral	HbA1c change	%	8.8	1.2	Not applicable	Not applicable	Not applicable	475
Rosenstock 2016	Canagliflozin; 100-300 mg daily combined; Oral	Weight change	kg	92.5	20	Not applicable	Not applicable	Not applicable	475

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Rosenstock 2016	Canagliflozin; 300 mg daily; Oral	BMI change	kg/m2	32.6	5.8	Not applicable	Not applicable	Not applicable	238
Rosenstock 2016	Canagliflozin; 300 mg daily; Oral	HbA1c change	%	8.8	1.2	Not applicable	Not applicable	Not applicable	238
Rosenstock 2016	Canagliflozin; 300 mg daily; Oral	Weight change	kg	93	19.9	Not applicable	Not applicable	Not applicable	238
Rosenstock 2016	Metformin type unspecified; 500-2000 mg daily; Oral	BMI change	kg/m2	33	6	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Metformin type unspecified; 500-2000 mg daily; Oral	HbA1c change	%	8.8	1.2	Not applicable	Not applicable	Not applicable	237
Rosenstock 2016	Metformin type unspecified; 500-2000 mg daily; Oral	Weight change	kg	92.1	20.1	Not applicable	Not applicable	Not applicable	237
Ross 2015	Linagliptin + Metformin; 1500-2000 mg daily; Oral	BMI change	kg/m2	29.84	5.82	Not applicable	Not applicable	Not applicable	159

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Ross 2015	Linagliptin + Metformin; 1500-2000 mg daily; Oral	HbA1c change	%	9.79	1.19	Not applicable	Not applicable	Not applicable	159
Ross 2015	Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	29.63	5.43	Not applicable	Not applicable	Not applicable	157
Ross 2015	Linagliptin; 5 mg daily; Oral	HbA1c change	%	9.88	1.1	Not applicable	Not applicable	Not applicable	157
Russell-Jones 2012	Exenatide; 2 mg weekly; Subcutaneous	BMI change	kg/m2	31.4	5.3	Not applicable	Not applicable	Not applicable	248
Russell-Jones 2012	Exenatide; 2 mg weekly; Subcutaneous	HbA1c change	%	8.5	1.2	Not applicable	Not applicable	Not applicable	248
Russell-Jones 2012	Exenatide; 2 mg weekly; Subcutaneous	Weight change	kg	87.5	18.9	Not applicable	Not applicable	Not applicable	248
Russell-Jones 2012	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	30.7	5.5	Not applicable	Not applicable	Not applicable	246

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Russell-Jones 2012	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	8.6	1.2	Not applicable	Not applicable	Not applicable	246
Russell-Jones 2012	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	85.9	19.6	Not applicable	Not applicable	Not applicable	246
Russell-Jones 2012	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	31.1	5.3	Not applicable	Not applicable	Not applicable	163
Russell-Jones 2012	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	8.5	1.2	Not applicable	Not applicable	Not applicable	163
Russell-Jones 2012	Pioglitazone; 45 mg daily; Oral	Weight change	kg	86.1	17.8	Not applicable	Not applicable	Not applicable	163
Russell-Jones 2012	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	31.8	5.4	Not applicable	Not applicable	Not applicable	163
Russell-Jones 2012	Sitagliptin; 100 mg daily; Oral	HbA1c change	%	8.5	1.3	Not applicable	Not applicable	Not applicable	163
Russell-Jones 2012	Sitagliptin; 100 mg daily; Oral	Weight change	kg	88.7	18.7	Not applicable	Not applicable	Not applicable	163

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Scherbaum 2002	Pioglitazone; 15 mg daily; Oral	HbA1c change	%	9.14	1.17	Not applicable	Not applicable	Not applicable	83
Scherbaum 2002	Pioglitazone; 15-30 mg daily combined; Oral	HbA1c change	%	9.1	1.15	Not applicable	Not applicable	Not applicable	159
Scherbaum 2002	Pioglitazone; 30 mg daily; Oral	HbA1c change	%	9.06	1.12	Not applicable	Not applicable	Not applicable	76
Scherbaum 2002	Placebo; None; Oral	HbA1c change	%	8.73	1.12	Not applicable	Not applicable	Not applicable	76
Schernthaner 2004	Metformin type unspecified; 2550 mg daily; Oral	BMI change	kg/m2	31.4	5.2	Not applicable	Not applicable	Not applicable	597
Schernthaner 2004	Metformin type unspecified; 2550 mg daily; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	597
Schernthaner 2004	Metformin type unspecified; 2550 mg daily; Oral	Weight change	kg	89.7	16.6	Not applicable	Not applicable	Not applicable	597

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Schernthaner 2004	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	31.2	4.9	Not applicable	Not applicable	Not applicable	597
Schernthaner 2004	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	8.7	1	Not applicable	Not applicable	Not applicable	597
Schernthaner 2004	Pioglitazone; 45 mg daily; Oral	Weight change	kg	88.2	15.5	Not applicable	Not applicable	Not applicable	597
Schwartz 2006	Metformin slow release; 1500 mg daily (in 2 doses); Oral	HbA1c change	%	8.5	3.24	0.24	Not applicable	Not applicable	182
Schwartz 2006	Metformin slow release; 1500 mg daily; Oral	HbA1c change	%	8.22	3.34	0.25	Not applicable	Not applicable	178
Schwartz 2006	Metformin slow release; 1500-2000 mg daily combined; Oral	HbA1c change	%	8.33	3.24	Not applicable	Not applicable	Not applicable	532
Schwartz 2006	Metformin slow release; 2000 mg daily; Oral	HbA1c change	%	8.26	3.15	0.24	Not applicable	Not applicable	172

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Schwartz 2006	Metformin standard release; 1500 mg daily (in 2 doses); Oral	HbA1c change	%	8.7	3.3	0.25	Not applicable	Not applicable	174
Schweizer 2007	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	32.5	5.7	Not applicable	Not applicable	Not applicable	254
Schweizer 2007	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	8.7	1.1	Not applicable	Not applicable	Not applicable	254
Schweizer 2007	Vildagliptin; 100 mg daily; Oral	BMI change	kg/m2	32.4	5.7	Not applicable	Not applicable	Not applicable	526
Schweizer 2007	Vildagliptin; 100 mg daily; Oral	HbA1c change	%	8.7	1.1	Not applicable	Not applicable	Not applicable	526
Schweizer 2009	Metformin type unspecified; 500-1500 mg daily; Oral	BMI change	kg/m2	29.4	4.6	Not applicable	Not applicable	Not applicable	166
Schweizer 2009	Metformin type	HbA1c change	%	7.7	0.6	Not applicable	Not applicable	Not applicable	166

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	unspecified; 500-1500 mg daily; Oral								
Schweizer 2009	Vildagliptin; 100 mg daily; Oral	BMI change	kg/m2	29.8	4.4	Not applicable	Not applicable	Not applicable	169
Schweizer 2009	Vildagliptin; 100 mg daily; Oral	HbA1c change	%	7.8	0.6	Not applicable	Not applicable	Not applicable	169
Seino 2018	Semaglutide; 0.5 mg weekly; Subcutaneous	BMI change	kg/m2	8.2	1	Not applicable	Not applicable	Not applicable	103
Seino 2018	Semaglutide; 0.5 mg weekly; Subcutaneous	HbA1c change	%	67.8	11.7	Not applicable	Not applicable	Not applicable	103
Seino 2018	Semaglutide; 0.5 mg weekly; Subcutaneous	Weight change	kg	25.1	3.8	Not applicable	Not applicable	Not applicable	103
Seino 2018	Semaglutide; 1.0 mg weekly; Subcutaneous	BMI change	kg/m2	8	0.9	Not applicable	Not applicable	Not applicable	102

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Seino 2018	Semaglutide; 1.0 mg weekly; Subcutaneous	HbA1c change	%	70.8	16.4	Not applicable	Not applicable	Not applicable	102
Seino 2018	Semaglutide; 1.0 mg weekly; Subcutaneous	Weight change	kg	26.1	5.2	Not applicable	Not applicable	Not applicable	102
Seino 2018	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	8.2	0.9	Not applicable	Not applicable	Not applicable	103
Seino 2018	Sitagliptin; 100 mg daily; Oral	HbA1c change	%	69.4	12.9	Not applicable	Not applicable	Not applicable	103
Seino 2018	Sitagliptin; 100 mg daily; Oral	Weight change	kg	25.1	3.6	Not applicable	Not applicable	Not applicable	103
Seino 2018	Semaglutide; 0.5 mg and 1.0 mg weekly combined; Subcutaneous	BMI change	kg/m2	8.1	0.95	Not applicable	Not applicable	Not applicable	205
Seino 2018	Semaglutide; 0.5 mg and 1.0 mg	HbA1c change	%	69.3	14.1	Not applicable	Not applicable	Not applicable	205

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	weekly combined; Subcutaneous								
Seino 2018	Semaglutide; 0.5 mg and 1.0 mg weekly combined; Subcutaneous	Weight change	kg	25.6	4.5	Not applicable	Not applicable	Not applicable	205
Shihara 2011	Glimepiride; 0.5-6 mg daily; Oral	BMI change	kg/m2	24.6	3.8	Not applicable	Not applicable	Not applicable	93
Shihara 2011	Glimepiride; 0.5-6 mg daily; Oral	HbA1c change	%	7.8	0.9	Not applicable	Not applicable	Not applicable	95
Shihara 2011	Glimepiride; 0.5-6 mg daily; Oral	Weight change	kg	65.6	12.5	Not applicable	Not applicable	Not applicable	93
Shihara 2011	Pioglitazone; 15-45 mg daily; Oral	BMI change	kg/m2	24.5	4.3	Not applicable	Not applicable	Not applicable	92
Shihara 2011	Pioglitazone; 15-45 mg daily; Oral	HbA1c change	%	7.8	0.9	Not applicable	Not applicable	Not applicable	95
Shihara 2011	Pioglitazone; 15-45 mg daily; Oral	Weight change	kg	65.5	14.6	Not applicable	Not applicable	Not applicable	92

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Sorli 2017	Placebo; None; Subcutaneous	BMI change	kg/m2	32.4	6.86	Not applicable	Not applicable	Not applicable	129
Sorli 2017	Placebo; None; Subcutaneous	HbA1c change	%	7.95	0.85	Not applicable	Not applicable	Not applicable	129
Sorli 2017	Placebo; None; Subcutaneous	Weight change	kg	89.05	22.16	Not applicable	Not applicable	Not applicable	129
Sorli 2017	Semaglutide; 0.5 mg weekly; Subcutaneous	BMI change	kg/m2	32.46	7.62	Not applicable	Not applicable	Not applicable	128
Sorli 2017	Semaglutide; 0.5 mg weekly; Subcutaneous	HbA1c change	%	8.09	0.89	Not applicable	Not applicable	Not applicable	128
Sorli 2017	Semaglutide; 0.5 mg weekly; Subcutaneous	Weight change	kg	89.81	22.96	Not applicable	Not applicable	Not applicable	128
Sorli 2017	Semaglutide; 0.5-1 mg	BMI change	kg/m2	33.2	8.06	Not applicable	Not applicable	Not applicable	258

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	weekly combined; Subcutaneous								
Sorli 2017	Semaglutide; 0.5-1 mg weekly combined; Subcutaneous	HbA1c change	%	8.11	0.85	Not applicable	Not applicable	Not applicable	258
Sorli 2017	Semaglutide; 0.5-1 mg weekly combined; Subcutaneous	Weight change	kg	93.37	24.53	Not applicable	Not applicable	Not applicable	258
Sorli 2017	Semaglutide; 1 mg weekly; Subcutaneous	BMI change	kg/m2	33.92	8.43	Not applicable	Not applicable	Not applicable	130
Sorli 2017	Semaglutide; 1 mg weekly; Subcutaneous	HbA1c change	%	8.12	0.81	Not applicable	Not applicable	Not applicable	130
Sorli 2017	Semaglutide; 1 mg weekly; Subcutaneous	Weight change	kg	96.87	25.59	Not applicable	Not applicable	Not applicable	130

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Stenlöf 2013	Canagliflozin; 100 mg daily; Oral	BMI change	kg/m2	31.3	6.6	Not applicable	Not applicable	Not applicable	195
Stenlöf 2013	Canagliflozin; 100 mg daily; Oral	HbA1c change	%	8.1	1	Not applicable	Not applicable	Not applicable	195
Stenlöf 2013	Canagliflozin; 100 mg daily; Oral	Weight change	kg	85.8	21.4	Not applicable	Not applicable	Not applicable	195
Stenlöf 2013	Canagliflozin; 100-300 mg daily combined; Oral	BMI change	kg/m2	31.5	6.3	Not applicable	Not applicable	Not applicable	392
Stenlöf 2013	Canagliflozin; 100-300 mg daily combined; Oral	HbA1c change	%	8.05	1	Not applicable	Not applicable	Not applicable	392
Stenlöf 2013	Canagliflozin; 100-300 mg daily combined; Oral	Weight change	kg	86.4	21	Not applicable	Not applicable	Not applicable	392
Stenlöf 2013	Canagliflozin; 300 mg daily; Oral	BMI change	kg/m2	31.7	6	Not applicable	Not applicable	Not applicable	197

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Stenlöf 2013	Canagliflozin; 300 mg daily; Oral	HbA1c change	%	8	1	Not applicable	Not applicable	Not applicable	197
Stenlöf 2013	Canagliflozin; 300 mg daily; Oral	Weight change	kg	86.9	20.5	Not applicable	Not applicable	Not applicable	197
Stenlöf 2013	Placebo; None; Oral	BMI change	kg/m2	31.8	6.2	Not applicable	Not applicable	Not applicable	192
Stenlöf 2013	Placebo; None; Oral	HbA1c change	%	8	1	Not applicable	Not applicable	Not applicable	192
Stenlöf 2013	Placebo; None; Oral	Weight change	kg	87.6	19.5	Not applicable	Not applicable	Not applicable	192
Suzuki 2014	Liraglutide; 0.9 mg daily; Subcutaneous	HbA1c change	%	9.8	2.2	Not applicable	Not applicable	Not applicable	24
Suzuki 2014	Liraglutide; 0.9 mg daily; Subcutaneous	Weight change	kg	82.3	19	Not applicable	Not applicable	Not applicable	24
Suzuki 2014	Sitagliptin; 50 mg daily; Oral	HbA1c change	%	9.1	1.6	Not applicable	Not applicable	Not applicable	16
Suzuki 2014	Sitagliptin; 50 mg daily; Oral	Weight change	kg	81.7	25.4	Not applicable	Not applicable	Not applicable	16

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Tan 2005	Gliclazide; 320 mg daily; Oral	BMI change	kg/m2	31	5.6	Not applicable	Not applicable	Not applicable	297
Tan 2005	Gliclazide; 320 mg daily; Oral	Weight change	kg	89.2	18.2	Not applicable	Not applicable	Not applicable	297
Tan 2005	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	32	6.4	Not applicable	Not applicable	Not applicable	270
Tan 2005	Pioglitazone; 45 mg daily; Oral	Weight change	kg	91.7	19.9	Not applicable	Not applicable	Not applicable	270
Tao 2018	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	26.4	4.55	0.77	25	28	25
Tao 2018	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	7.3	0.2	Not applicable	Not applicable	Not applicable	25
Tao 2018	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	67.9	11.03	2.19	63.6	72.2	25
Tao 2018	Saxagliptin + Metformin; 5	BMI change	kg/m2	26.38	4.41	0.77	25	28	25

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	mg + 2000 mg daily; Oral								
Tao 2018	Saxagliptin + Metformin; 5 mg + 2000 mg daily; Oral	HbA1c change	%	7.4	0.3	Not applicable	Not applicable	Not applicable	25
Tao 2018	Saxagliptin + Metformin; 5 mg + 2000 mg daily; Oral	Weight change	kg	69.3	12.18	2.42	64.6	74.1	25
Tao 2018	Saxagliptin; 5 mg daily; Oral	BMI change	kg/m2	27.2	5.79	1.02	25	29	25
Tao 2018	Saxagliptin; 5 mg daily; Oral	HbA1c change	%	7.4	0.3	Not applicable	Not applicable	Not applicable	25
Tao 2018	Saxagliptin; 5 mg daily; Oral	Weight change	kg	70.4	17.18	3.42	63.7	77.1	25
Terauchi 2017	Glimepiride; 0.5-6 mg daily; Oral	BMI change	kg/m2	24.2	3.6	Not applicable	Not applicable	Not applicable	129
Terauchi 2017	Glimepiride; 0.5-6 mg daily; Oral	HbA1c change	%	7.5	0.7	Not applicable	Not applicable	Not applicable	129

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Terauchi 2017	Glimepiride; 0.5-6 mg daily; Oral	Weight change	kg	60.9	9.7	Not applicable	Not applicable	Not applicable	129
Terauchi 2017	Sitagliptin; 25-100 mg daily; Oral	BMI change	kg/m2	24.1	3.3	Not applicable	Not applicable	Not applicable	143
Terauchi 2017	Sitagliptin; 25-100 mg daily; Oral	HbA1c change	%	7.5	0.7	Not applicable	Not applicable	Not applicable	143
Terauchi 2017	Sitagliptin; 25-100 mg daily; Oral	Weight change	kg	60.9	9.7	Not applicable	Not applicable	Not applicable	143
Umpierrez 2014	Dulaglutide; 0.75 mg weekly; Subcutaneous	BMI change	kg/m2	33	6	Not applicable	Not applicable	Not applicable	270
Umpierrez 2014	Dulaglutide; 0.75 mg weekly; Subcutaneous	HbA1c change	%	7.6	0.9	Not applicable	Not applicable	Not applicable	270
Umpierrez 2014	Dulaglutide; 0.75 mg weekly; Subcutaneous	Weight change	kg	92	19	Not applicable	Not applicable	Not applicable	270
Umpierrez 2014	Dulaglutide; 0.75-1.5 mg	BMI change	kg/m2	33.5	6.02	Not applicable	Not applicable	Not applicable	539

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	weekly combined; Subcutaneous								
Umpierrez 2014	Dulaglutide; 0.75-1.5 mg weekly combined; Subcutaneous	HbA1c change	%	7.6	0.9	Not applicable	Not applicable	Not applicable	539
Umpierrez 2014	Dulaglutide; 0.75-1.5 mg weekly combined; Subcutaneous	Weight change	kg	92.5	18.99	Not applicable	Not applicable	Not applicable	539
Umpierrez 2014	Dulaglutide; 1.5 mg weekly; Subcutaneous	BMI change	kg/m2	34	6	Not applicable	Not applicable	Not applicable	269
Umpierrez 2014	Dulaglutide; 1.5 mg weekly; Subcutaneous	HbA1c change	%	7.6	0.9	Not applicable	Not applicable	Not applicable	269
Umpierrez 2014	Dulaglutide; 1.5 mg weekly;	Weight change	kg	93	19	Not applicable	Not applicable	Not applicable	269

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	Subcutaneous								
Umpierrez 2014	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	33	5	Not applicable	Not applicable	Not applicable	268
Umpierrez 2014	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	7.6	0.8	Not applicable	Not applicable	Not applicable	268
Umpierrez 2014	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	92	19	Not applicable	Not applicable	Not applicable	268
Wainstein 2012	Pioglitazone; 45 mg daily; Oral	BMI change	kg/m2	29.6	5.5	Not applicable	Not applicable	Not applicable	256
Wainstein 2012	Pioglitazone; 45 mg daily; Oral	HbA1c change	%	8.9	1.3	Not applicable	Not applicable	Not applicable	256
Wainstein 2012	Pioglitazone; 45 mg daily; Oral	Weight change	kg	81.4	19.9	Not applicable	Not applicable	Not applicable	256
Wainstein 2012	Sitagliptin + Metformin; 100 mg +	BMI change	kg/m2	30	6.1	Not applicable	Not applicable	Not applicable	261

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	2000 mg daily; Oral								
Wainstein 2012	Sitagliptin + Metformin; 100 mg + 2000 mg daily; Oral	HbA1c change	%	9	1.3	Not applicable	Not applicable	Not applicable	261
Wainstein 2012	Sitagliptin + Metformin; 100 mg + 2000 mg daily; Oral	Weight change	kg	82.8	21.1	Not applicable	Not applicable	Not applicable	261
Wang 2013	Gliclazide; 120 mg daily; Oral	HbA1c change	%	8.4	0.93	Not applicable	Not applicable	Not applicable	30
Wang 2013	Gliclazide; 120 mg daily; Oral	Weight change	kg	70.4	11.7	Not applicable	Not applicable	Not applicable	30
Wang 2013	Metformin type unspecified; 1700 mg daily; Oral	HbA1c change	%	8.07	0.77	Not applicable	Not applicable	Not applicable	30
Wang 2013	Metformin type unspecified; 1700 mg daily; Oral	Weight change	kg	71.6	12.7	Not applicable	Not applicable	Not applicable	30

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Wang 2016A	Dapagliflozin; 5-10 mg daily; Oral	HbA1c change	mmol/mol	67	5	Not applicable	Not applicable	Not applicable	18
Wang 2016A	Dapagliflozin; 5-10 mg daily; Oral	Weight change	kg	66.4	10.1	Not applicable	Not applicable	Not applicable	18
Wang 2016A	Placebo; None; Oral	HbA1c change	mmol/mol	68	7	Not applicable	Not applicable	Not applicable	10
Wang 2016A	Placebo; None; Oral	Weight change	kg	64.7	7.1	Not applicable	Not applicable	Not applicable	10
Wang 2022A	Metformin type unspecified; 1500 mg daily; Oral	BMI change	kg/m2	25.41	3.45	Not applicable	Not applicable	Not applicable	17
Wang 2022A	Metformin type unspecified; 1500 mg daily; Oral	HbA1c change	%	8.6	1.17	Not applicable	Not applicable	Not applicable	17
Wang 2022A	Sitagliptin + Metformin; 100 mg + 1500 mg daily; Oral	HbA1c change	%	7.83	0.58	Not applicable	Not applicable	Not applicable	20
Wang 2022A	Sitagliptin; 100 mg daily; Oral	BMI change	kg/m2	26.07	3.24	Not applicable	Not applicable	Not applicable	20

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Wang 2022A	Sitagliptin; 100 mg daily; Oral	HbA1c change	%	7.93	0.91	Not applicable	Not applicable	Not applicable	17
Wang 2022A	Standard care; None; Oral	BMI change	kg/m2	26.46	2.86	Not applicable	Not applicable	Not applicable	17
Wolever 2000	Metformin type unspecified; 1500 mg daily; Oral	BMI change	kg/m2	30.5	4.72	0.6	Not applicable	Not applicable	62
Wolever 2000	Metformin type unspecified; 1500 mg daily; Oral	HbA1c change	%	8.2	0.79	0.1	Not applicable	Not applicable	62
Wolever 2000	Placebo; None; Oral	BMI change	kg/m2	30.8	4.02	0.6	Not applicable	Not applicable	45
Wolever 2000	Placebo; None; Oral	HbA1c change	%	7.8	0.67	0.1	Not applicable	Not applicable	45
Wu 2015	Linagliptin; 5 mg daily; Oral	BMI change	kg/m2	24.37	2.09	Not applicable	Not applicable	Not applicable	34
Wu 2015	Linagliptin; 5 mg daily; Oral	HbA1c change	%	7.97	0.68	Not applicable	Not applicable	Not applicable	34

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Wu 2015	Linagliptin; 5 mg daily; Oral	Weight change	kg	67.05	8.12	Not applicable	Not applicable	Not applicable	34
Wu 2015	Placebo; None; Oral	BMI change	kg/m2	24.11	2.28	Not applicable	Not applicable	Not applicable	23
Wu 2015	Placebo; None; Oral	HbA1c change	%	8	0.69	Not applicable	Not applicable	Not applicable	23
Wu 2015	Placebo; None; Oral	Weight change	kg	65.24	8.45	Not applicable	Not applicable	Not applicable	23
Xu 2015	Exenatide; 10-20 mcg daily; Subcutaneous	BMI change	kg/m2	25.9	3.15	0.3	Not applicable	Not applicable	110
Xu 2015	Exenatide; 10-20 mcg daily; Subcutaneous	HbA1c change	%	8	1.05	0.1	Not applicable	Not applicable	110
Xu 2015	Exenatide; 10-20 mcg daily; Subcutaneous	Weight change	kg	71.7	11.54	1.1	Not applicable	Not applicable	110
Xu 2015	Insulin glargine; Titrated; Subcutaneous	BMI change	kg/m2	25.4	3.2	0.3	Not applicable	Not applicable	114

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Xu 2015	Insulin glargine; Titrated; Subcutaneous	HbA1c change	%	8.2	1.07	0.1	Not applicable	Not applicable	114
Xu 2015	Insulin glargine; Titrated; Subcutaneous	Weight change	kg	69.8	10.68	1	Not applicable	Not applicable	114
Xu 2015	Pioglitazone; 30-45 mg daily; Oral	BMI change	kg/m2	25.9	3.26	0.3	Not applicable	Not applicable	118
Xu 2015	Pioglitazone; 30-45 mg daily; Oral	HbA1c change	%	8	1.09	0.1	Not applicable	Not applicable	118
Xu 2015	Pioglitazone; 30-45 mg daily; Oral	Weight change	kg	70.6	11.95	1.1	Not applicable	Not applicable	118
Yamada 2020	Liraglutide + Metformin; 0.9 mg daily; Subcutaneous	BMI change	kg/m2	26.9	4.8	Not applicable	Not applicable	Not applicable	48
Yamada 2020	Liraglutide + Metformin; 0.9 mg daily; Subcutaneous	HbA1c change	%	8.3	0.8	Not applicable	Not applicable	Not applicable	48

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Yamada 2020	Liraglutide + Metformin; 0.9 mg daily; Subcutaneous	Weight change	kg	74.7	15.4	Not applicable	Not applicable	Not applicable	48
Yamada 2020	Placebo; None; Subcutaneous	BMI change	kg/m2	25.1	3.9	Not applicable	Not applicable	Not applicable	49
Yamada 2020	Placebo; None; Subcutaneous	HbA1c change	%	8.3	1.1	Not applicable	Not applicable	Not applicable	49
Yamada 2020	Placebo; None; Subcutaneous	Weight change	kg	70.3	12.4	Not applicable	Not applicable	Not applicable	49
Yamada 2020	Semaglutide; 14 mg daily; Oral	BMI change	kg/m2	24.7	4.1	Not applicable	Not applicable	Not applicable	48
Yamada 2020	Semaglutide; 14 mg daily; Oral	HbA1c change	%	8	0.9	Not applicable	Not applicable	Not applicable	48
Yamada 2020	Semaglutide; 14 mg daily; Oral	Weight change	kg	68	13	Not applicable	Not applicable	Not applicable	48
Yamada 2020	Semaglutide; 3 mg daily; Oral	BMI change	kg/m2	26.5	4.6	Not applicable	Not applicable	Not applicable	49

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Yamada 2020	Semaglutide; 3 mg daily; Oral	HbA1c change	%	8.1	0.8	Not applicable	Not applicable	Not applicable	49
Yamada 2020	Semaglutide; 3 mg daily; Oral	Weight change	kg	71.4	14.3	Not applicable	Not applicable	Not applicable	49
Yamada 2020	Semaglutide; 3-14 mg daily combined; Oral	BMI change	kg/m2	25.84	4.14	Not applicable	Not applicable	Not applicable	146
Yamada 2020	Semaglutide; 3-14 mg daily combined; Oral	HbA1c change	%	8.13	0.91	Not applicable	Not applicable	Not applicable	146
Yamada 2020	Semaglutide; 3-14 mg daily combined; Oral	Weight change	kg	70.25	12.79	Not applicable	Not applicable	Not applicable	146
Yamada 2020	Semaglutide; 7 mg daily; Oral	BMI change	kg/m2	26.3	3.5	Not applicable	Not applicable	Not applicable	49
Yamada 2020	Semaglutide; 7 mg daily; Oral	HbA1c change	%	8.3	1	Not applicable	Not applicable	Not applicable	49
Yamada 2020	Semaglutide; 7 mg daily; Oral	Weight change	kg	71.3	10.8	Not applicable	Not applicable	Not applicable	49

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Yamanouchi 2005	Glimepiride; 1-2 mg daily; Oral	BMI change	kg/m2	25.6	3.5	Not applicable	Not applicable	Not applicable	37
Yamanouchi 2005	Glimepiride; 1-2 mg daily; Oral	HbA1c change	%	9.8	0.7	Not applicable	Not applicable	Not applicable	37
Yamanouchi 2005	Metformin type unspecified; 750 mg daily; Oral	BMI change	kg/m2	26.2	3.8	Not applicable	Not applicable	Not applicable	39
Yamanouchi 2005	Metformin type unspecified; 750 mg daily; Oral	HbA1c change	%	9.9	0.7	Not applicable	Not applicable	Not applicable	39
Yamanouchi 2005	Pioglitazone; 30-45 mg daily combined; Oral	BMI change	kg/m2	25.8	4.2	Not applicable	Not applicable	Not applicable	38
Yamanouchi 2005	Pioglitazone; 30-45 mg daily combined; Oral	HbA1c change	%	10.2	0.8	Not applicable	Not applicable	Not applicable	38
Yoon 2011A	Glimepiride; 8 mg daily; Oral	BMI change	kg/m2	25.5	3.1	Not applicable	Not applicable	Not applicable	118

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Yoon 2011A	Glimepiride; 8 mg daily; Oral	HbA1c change	%	7.8	0.8	Not applicable	Not applicable	Not applicable	118
Yoon 2011A	Glimepiride; 8 mg daily; Oral	Weight change	kg	67.9	10.9	Not applicable	Not applicable	Not applicable	118
Yoon 2011A	Metformin type unspecified; 2000 mg daily; Oral	BMI change	kg/m2	25.7	3.2	Not applicable	Not applicable	Not applicable	114
Yoon 2011A	Metformin type unspecified; 2000 mg daily; Oral	HbA1c change	%	7.9	0.8	Not applicable	Not applicable	Not applicable	114
Yoon 2011A	Metformin type unspecified; 2000 mg daily; Oral	Weight change	kg	68.9	11.1	Not applicable	Not applicable	Not applicable	114
Yoon 2012	Pioglitazone + Sitagliptin; 100 mg + 30-45 mg daily; Oral	BMI change	kg/m2	29.7	4.8	Not applicable	Not applicable	Not applicable	164
Yoon 2012	Pioglitazone + Sitagliptin; 100 mg + 30-	HbA1c change	%	9.4	1.1	Not applicable	Not applicable	Not applicable	164

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	45 mg daily; Oral								
Yoon 2012	Pioglitazone + Sitagliptin; 100 mg + 30-45 mg daily; Oral	Weight change	kg	81.6	17.4	Not applicable	Not applicable	Not applicable	164
Yoon 2012	Pioglitazone; 30-45 mg daily; Oral	BMI change	kg/m2	29.9	5.3	Not applicable	Not applicable	Not applicable	153
Yoon 2012	Pioglitazone; 30-45 mg daily; Oral	HbA1c change	%	9.4	1.4	Not applicable	Not applicable	Not applicable	153
Yoon 2012	Pioglitazone; 30-45 mg daily; Oral	Weight change	kg	81.9	18.4	Not applicable	Not applicable	Not applicable	153
Yuan 2012	Exenatide; 20 mcg daily; Subcutaneous	BMI change	kg/m2	30.6	2.8	Not applicable	Not applicable	Not applicable	33
Yuan 2012	Exenatide; 20 mcg daily; Subcutaneous	HbA1c change	%	8.27	1.58	Not applicable	Not applicable	Not applicable	33
Yuan 2012	Exenatide; 20 mcg daily; Subcutaneous	Weight change	kg	82.2	12.8	Not applicable	Not applicable	Not applicable	33

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
Yuan 2012	Metformin type unspecified; 1500 mg daily; Oral	BMI change	kg/m2	29.3	2.6	Not applicable	Not applicable	Not applicable	26
Yuan 2012	Metformin type unspecified; 1500 mg daily; Oral	HbA1c change	%	8.11	1.92	Not applicable	Not applicable	Not applicable	26
Yuan 2012	Metformin type unspecified; 1500 mg daily; Oral	Weight change	kg	83.7	10.7	Not applicable	Not applicable	Not applicable	26
Zhang 2020A	Liraglutide; 0.6-1.2 mg daily; Subcutaneous	BMI change	kg/m2	27.6	5.2	Not applicable	Not applicable	Not applicable	30
Zhang 2020A	Liraglutide; 0.6-1.2 mg daily; Subcutaneous	HbA1c change	%	8.1	2	Not applicable	Not applicable	Not applicable	30
Zhang 2020A	Liraglutide; 0.6-1.2 mg daily;	Weight change	kg	79.3	8.8	Not applicable	Not applicable	Not applicable	30

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	Subcutaneous								
Zhang 2020A	Pioglitazone; 15-30 mg daily; Oral	BMI change	kg/m2	27.1	3.8	Not applicable	Not applicable	Not applicable	30
Zhang 2020A	Pioglitazone; 15-30 mg daily; Oral	HbA1c change	%	8.1	1.7	Not applicable	Not applicable	Not applicable	30
Zhang 2020A	Pioglitazone; 15-30 mg daily; Oral	Weight change	kg	78	9.2	Not applicable	Not applicable	Not applicable	30
Zhou 2021	Canagliflozin + Metformin; 100 mg + 500-2000 mg daily; Oral	BMI change	kg/m2	27.3	5.36	Not applicable	Not applicable	Not applicable	12
Zhou 2021	Canagliflozin + Metformin; 100 mg + 500-2000 mg daily; Oral	HbA1c change	%	8.1	0.8	Not applicable	Not applicable	Not applicable	12
Zhou 2021	Canagliflozin + Metformin; 100 mg + 500-2000 mg daily; Oral	Weight change	kg	79.95	16.82	Not applicable	Not applicable	Not applicable	12
Zhou 2021	Glimepiride + Metformin; 1-4 mg + 500-	BMI change	kg/m2	26.3	3.3	Not applicable	Not applicable	Not applicable	13

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	2000 mg daily; Oral								
Zhou 2021	Glimepiride + Metformin; 1-4 mg + 500-2000 mg daily; Oral	HbA1c change	%	8.1	0.69	Not applicable	Not applicable	Not applicable	13
Zhou 2021	Glimepiride + Metformin; 1-4 mg + 500-2000 mg daily; Oral	Weight change	kg	76.5	16.37	Not applicable	Not applicable	Not applicable	13
Zhou 2022	Dapagliflozin + Metformin; 10 mg + 500 mg daily; Oral	BMI change	kg/m2	27.69	1.45	Not applicable	Not applicable	Not applicable	75
Zhou 2022	Metformin type unspecified; 500 mg daily; Oral	BMI change	kg/m2	27.61	1.49	Not applicable	Not applicable	Not applicable	75
Zougrafou 2015	Metformin type unspecified; 1700 mg daily; Oral	BMI change	kg/m2	32.2	5.9	Not applicable	Not applicable	Not applicable	32
Zougrafou 2015	Metformin type	HbA1c change	%	8	0.8	Not applicable	Not applicable	Not applicable	32

Study name	Drug details	Outcome	Units	Mean	SD	SE	2.5% Confidence interval	97.5% Confidence interval	n
	unspecified; 1700 mg daily; Oral								
Zougrafou 2015	Metformin type unspecified; 1700 mg daily; Oral	Weight change	kg	93.9	20.7	Not applicable	Not applicable	Not applicable	32
Zougrafou 2015	Vildagliptin + Metformin; 100 mg + 1700 mg daily; Oral	BMI change	kg/m2	31.6	4.6	Not applicable	Not applicable	Not applicable	32
Zougrafou 2015	Vildagliptin + Metformin; 100 mg + 1700 mg daily; Oral	HbA1c change	%	8.1	0.8	Not applicable	Not applicable	Not applicable	32
Zougrafou 2015	Vildagliptin + Metformin; 100 mg + 1700 mg daily; Oral	Weight change	kg	90.1	14.3	Not applicable	Not applicable	Not applicable	32